{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":"2","capability_id":null,"extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"R","per_page":12,"people":[{"id":445247,"version":1,"owner_type":"Person","owner_id":7299,"payload":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children\u0026rsquo;s, psychiatric, and rural hospitals along with healthcare provider associations.\u003c/p\u003e\n\u003cp\u003eAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\u003c/p\u003e\n\u003cp\u003eRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\u003c/p\u003e\n\u003cp\u003eWhen away from the office, Renee enjoys spending time with family and attending concerts.\u003c/p\u003e\n\u003cp\u003eRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean\u0026rsquo;s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship.\u003c/p\u003e","slug":"renee-rayne","email":"rrayne@kslaw.com","phone":null,"matters":["\u003cp\u003eAssisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.\u003c/p\u003e","\u003cp\u003eStructuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals\u0026rsquo; uncompensated costs of treating uninsured patients.\u003c/p\u003e","\u003cp\u003eDrafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.\u003c/p\u003e","\u003cp\u003eResearching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.\u003c/p\u003e","\u003cp\u003eNegotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.\u003c/p\u003e","\u003cp\u003eAdvising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.\u003c/p\u003e","\u003cp\u003eAssisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":3,"source":"smartTags"},{"id":826,"guid":"826.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Rayne","nick_name":"Renee","clerkships":[],"first_name":"Renee","title_rank":9999,"updated_by":34,"law_schools":[{"id":2055,"meta":{"degree":"J.D.","honors":"with honors","is_law_school":"1","graduation_date":"2014-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"“Ones to Watch in America,” Healthcare Law","detail":"Best Lawyers, 2022-2026"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children\u0026rsquo;s, psychiatric, and rural hospitals along with healthcare provider associations.\u003c/p\u003e\n\u003cp\u003eAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\u003c/p\u003e\n\u003cp\u003eRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\u003c/p\u003e\n\u003cp\u003eWhen away from the office, Renee enjoys spending time with family and attending concerts.\u003c/p\u003e\n\u003cp\u003eRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean\u0026rsquo;s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship.\u003c/p\u003e","matters":["\u003cp\u003eAssisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.\u003c/p\u003e","\u003cp\u003eStructuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals\u0026rsquo; uncompensated costs of treating uninsured patients.\u003c/p\u003e","\u003cp\u003eDrafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.\u003c/p\u003e","\u003cp\u003eResearching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.\u003c/p\u003e","\u003cp\u003eNegotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.\u003c/p\u003e","\u003cp\u003eAdvising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.\u003c/p\u003e","\u003cp\u003eAssisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.\u003c/p\u003e"],"recognitions":[{"title":"“Ones to Watch in America,” Healthcare Law","detail":"Best Lawyers, 2022-2026"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":13321}]},"capability_group_id":2},"created_at":"2026-01-26T14:39:50.000Z","updated_at":"2026-01-26T14:39:50.000Z","searchable_text":"Rayne{{ FIELD }}{:title=\u0026gt;\"“Ones to Watch in America,” Healthcare Law\", :detail=\u0026gt;\"Best Lawyers, 2022-2026\"}{{ FIELD }}Assisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.{{ FIELD }}Structuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals’ uncompensated costs of treating uninsured patients.{{ FIELD }}Drafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.{{ FIELD }}Researching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.{{ FIELD }}Negotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.{{ FIELD }}Advising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.{{ FIELD }}Assisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.{{ FIELD }}A partner in the firm’s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.\nRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children’s, psychiatric, and rural hospitals along with healthcare provider associations.\nAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\nRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\nWhen away from the office, Renee enjoys spending time with family and attending concerts.\nRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean’s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship. Partner “Ones to Watch in America,” Healthcare Law Best Lawyers, 2022-2026 Vanderbilt University Vanderbilt University School of Law The University of Texas at Austin The University of Texas School of Law Tennessee Texas Texas State Bar American Health Lawyers Association Assisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval. Structuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals’ uncompensated costs of treating uninsured patients. Drafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals. Researching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board. Negotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program. Advising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs. Assisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.","searchable_name":"Renee Rayne","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":432953,"version":1,"owner_type":"Person","owner_id":986,"payload":{"bio":"\u003cp\u003eNikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25\u0026nbsp;years of experience.\u0026nbsp; Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.\u0026nbsp; Nikki previously co-chaired\u0026nbsp;the firm\u0026rsquo;s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450\u0026nbsp;lawyers across seventeen practice areas in the firm.\u0026nbsp; In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.\u0026nbsp; Nikki is ranked nationally by \u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a\u0026nbsp;\u003cem\u003eLMG Life Sciences Star\u003c/em\u003e in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a\u0026nbsp;\u003cem\u003eLaw360 Compliance MVP\u003c/em\u003e\u0026nbsp;in 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.\u0026nbsp; Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.\u0026nbsp; She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.\u0026nbsp; She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.\u0026nbsp; She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.\u0026nbsp; She routinely advises company executives and board members and represents her clients before federal agencies.\u0026nbsp; She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\u003c/p\u003e\n\u003cp\u003eNikki leads two pharma and device industry coalitions on transparency and disclosure laws.\u0026nbsp; The\u0026nbsp;\u003cem\u003eAd Hoc Sunshine and State Law Compliance Group\u003c/em\u003e is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.\u0026nbsp; The \u003cem\u003eInternational Marketing and Disclosure Compliance Group\u003c/em\u003e is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\u003c/p\u003e\n\u003cp\u003eKing \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice has been named \u003cem\u003eLaw360\u003c/em\u003e Practice Group of the Year from 2017-2020.\u0026nbsp; King \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.\u0026nbsp; According to\u0026nbsp;\u003cem\u003eChambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA\u003c/em\u003e\u0026nbsp;(2022)\u003c/p\u003e\n\u003cp\u003eNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.\u0026nbsp; Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board\u0026nbsp;and has served\u0026nbsp;on the\u0026nbsp;Advisory Board for FDAnews and the PCF Pharma Congress planning committee.\u0026nbsp; She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the \u003cem\u003eFDLI Food \u0026amp; Drug Law Journal\u003c/em\u003e and a member of the FDLI Medical Device Committee.\u0026nbsp; Nikki has also served on the Leadership Advisory Board for the National Women\u0026rsquo;s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten\u0026nbsp;years.\u003c/p\u003e\n\u003cp\u003eNikki was elected by her partners in 2017 to serve for three years\u0026nbsp;on the firm\u0026rsquo;s Policy Committee, which is the firm's executive management committee.\u0026nbsp; Nikki served for many years on the firm\u0026rsquo;s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office.\u003c/p\u003e","slug":"nikki-reeves","email":"nreeves@kslaw.com","phone":null,"matters":["\u003cp\u003eAdvised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.\u003c/p\u003e","\u003cp\u003eAdvised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.\u003c/p\u003e","\u003cp\u003eAdvised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.\u003c/p\u003e","\u003cp\u003eConducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.\u003c/p\u003e","\u003cp\u003eStand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.\u003c/p\u003e","\u003cp\u003eLed risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":245}]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":1,"source":"smartTags"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":4,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":7,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":8,"source":"smartTags"},{"id":109,"guid":"109.capabilities","index":9,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":10,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":11,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":12,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":13,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":14,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":15,"source":"smartTags"},{"id":135,"guid":"135.capabilities","index":16,"source":"capabilities"}],"is_active":true,"last_name":"Reeves","nick_name":"Nikki","clerkships":[],"first_name":"Nikki","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Women, Influence \u0026 Power in Law Award for Thought Leadership","detail":"Corporate Counsel 2024"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eNikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25\u0026nbsp;years of experience.\u0026nbsp; Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.\u0026nbsp; Nikki previously co-chaired\u0026nbsp;the firm\u0026rsquo;s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450\u0026nbsp;lawyers across seventeen practice areas in the firm.\u0026nbsp; In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.\u0026nbsp; Nikki is ranked nationally by \u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a\u0026nbsp;\u003cem\u003eLMG Life Sciences Star\u003c/em\u003e in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a\u0026nbsp;\u003cem\u003eLaw360 Compliance MVP\u003c/em\u003e\u0026nbsp;in 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.\u0026nbsp; Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.\u0026nbsp; She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.\u0026nbsp; She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.\u0026nbsp; She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.\u0026nbsp; She routinely advises company executives and board members and represents her clients before federal agencies.\u0026nbsp; She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\u003c/p\u003e\n\u003cp\u003eNikki leads two pharma and device industry coalitions on transparency and disclosure laws.\u0026nbsp; The\u0026nbsp;\u003cem\u003eAd Hoc Sunshine and State Law Compliance Group\u003c/em\u003e is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.\u0026nbsp; The \u003cem\u003eInternational Marketing and Disclosure Compliance Group\u003c/em\u003e is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\u003c/p\u003e\n\u003cp\u003eKing \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice has been named \u003cem\u003eLaw360\u003c/em\u003e Practice Group of the Year from 2017-2020.\u0026nbsp; King \u0026amp; Spalding\u0026rsquo;s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.\u0026nbsp; According to\u0026nbsp;\u003cem\u003eChambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA\u003c/em\u003e\u0026nbsp;(2022)\u003c/p\u003e\n\u003cp\u003eNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.\u0026nbsp; Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board\u0026nbsp;and has served\u0026nbsp;on the\u0026nbsp;Advisory Board for FDAnews and the PCF Pharma Congress planning committee.\u0026nbsp; She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the \u003cem\u003eFDLI Food \u0026amp; Drug Law Journal\u003c/em\u003e and a member of the FDLI Medical Device Committee.\u0026nbsp; Nikki has also served on the Leadership Advisory Board for the National Women\u0026rsquo;s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten\u0026nbsp;years.\u003c/p\u003e\n\u003cp\u003eNikki was elected by her partners in 2017 to serve for three years\u0026nbsp;on the firm\u0026rsquo;s Policy Committee, which is the firm's executive management committee.\u0026nbsp; Nikki served for many years on the firm\u0026rsquo;s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office.\u003c/p\u003e","matters":["\u003cp\u003eAdvised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.\u003c/p\u003e","\u003cp\u003eAdvised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.\u003c/p\u003e","\u003cp\u003eAdvised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.\u003c/p\u003e","\u003cp\u003eConducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.\u003c/p\u003e","\u003cp\u003eStand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.\u003c/p\u003e","\u003cp\u003eLed risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.\u003c/p\u003e"],"recognitions":[{"title":"Women, Influence \u0026 Power in Law Award for Thought Leadership","detail":"Corporate Counsel 2024"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1139}]},"capability_group_id":2},"created_at":"2025-07-29T16:08:40.000Z","updated_at":"2025-07-29T16:08:40.000Z","searchable_text":"Reeves{{ FIELD }}{:title=\u0026gt;\"Women, Influence \u0026amp; Power in Law Award for Thought Leadership\", :detail=\u0026gt;\"Corporate Counsel 2024\"}{{ FIELD }}Advised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications.{{ FIELD }}Advised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct.{{ FIELD }}Advised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations.{{ FIELD }}Conducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies.{{ FIELD }}Stand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program.{{ FIELD }}Conducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations.{{ FIELD }}Led risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.{{ FIELD }}Nikki Reeves is an FDA and healthcare regulatory compliance lawyer with more than 25 years of experience.  Nikki co-chairs the firm's Government Matters \u0026amp; Regulatory practice management group, which is comprised of 200+ lawyers and consultants in eight practice areas.  Nikki previously co-chaired the firm’s Life Sciences and Healthcare Industry Group for six years, which is comprised of more than 450 lawyers across seventeen practice areas in the firm.  In 2024, Nikki was a winner of Corporate Counsel's 2024 Women, Influence \u0026amp; Power in Law Award for Law Firm Thought Leadership.  Nikki is ranked nationally by Chambers USA for Life Sciences: Regulatory Compliance and for Pharmaceuticals/Medical Products Regulatory from 2021-2025, named a LMG Life Sciences Star in FDA Pharmaceutical and in FDA Medical Device from 2019-2025, and was named a Law360 Compliance MVP in 2020. \nAs Deputy Chair of our FDA \u0026amp; Life Sciences practice, Nikki advises pharmaceutical and medical device companies on pre- and post-market FDA regulatory compliance and enforcement matters ranging from clinical trials, good manufacturing practices, to labeling, advertising, and promotion of FDA-regulated products.  Nikki has been the lead FDA regulatory advisor to her clients on 250+ transactional matters.  She conducts investigations into FDA clinical trials and post-marking noncompliance, acts as lead compliance and regulatory counsel for several companies under Corporate Integrity Agreements (CIAs) and has led several CMS Open Payments compliance audits.  She is an expert on federal Open Payments, state, and international transparency/disclosure laws and leads two pharma and device industry compliance coalitions. \nNikki counsels pharma and device companies on FDA inspections, Form 483s, Warning Letters, product recalls, import detentions, clinical holds, and other FDA compliance and enforcement matters.  She conducts risk assessments and internal investigations into allegations of FDA and healthcare program noncompliance.  She routinely advises company executives and board members and represents her clients before federal agencies.  She has established robust compliance programs and policies for numerous life sciences companies. Nikki has also served as an interim General Counsel and as a Chief Compliance Officer for her life sciences clients.\nNikki leads two pharma and device industry coalitions on transparency and disclosure laws.  The Ad Hoc Sunshine and State Law Compliance Group is a coalition she advises on federal Sunshine Act and state transparency/disclosure and gift ban laws.  The International Marketing and Disclosure Compliance Group is a separate coalition of companies she advises on the growing area of transparency and disclosure laws and industry codes of conduct in the EU, Australia, Japan, and numerous other countries and regions.\nKing \u0026amp; Spalding’s FDA \u0026amp; Life Sciences Practice has been named Law360 Practice Group of the Year from 2017-2020.  King \u0026amp; Spalding’s FDA \u0026amp; Life Sciences Practice is ranked by Chambers Legal, LMG Life Sciences, U.S. News, and Best Lawyers.  According to Chambers USA, sources praise Nikki as being \"thoughtful, quick to respond and available.\" -- Chambers USA (2022)\nNikki is a frequent speaker and author on FDA advertising/promotion, clinical trials, compliance, and transparency law matters.  Nikki was also selected to Law360's 2021 Compliance Editorial Advisory Board and has served on the Advisory Board for FDAnews and the PCF Pharma Congress planning committee.  She was formerly on the Food and Drug Law Institute (FDLI) Editorial Advisory Board for the FDLI Food \u0026amp; Drug Law Journal and a member of the FDLI Medical Device Committee.  Nikki has also served on the Leadership Advisory Board for the National Women’s Law Center and on the Special Gifts Committee for the Arlington Free Clinic for more than ten years.\nNikki was elected by her partners in 2017 to serve for three years on the firm’s Policy Committee, which is the firm's executive management committee.  Nikki served for many years on the firm’s Lateral Partner Committee and on the firm's Partners Committee, and was also the Hiring Partner for the Washington, D.C. office. Kelly Reeves Partner Women, Influence \u0026amp; Power in Law Award for Thought Leadership Corporate Counsel 2024 North Carolina State University  University of Maryland  North Carolina State University  District of Columbia Maryland Advised companies on FDA advertising and promotion rules for drugs, devices, and cosmetics, including social media, new product launches, DTC, physician and payor communications, broadcast ads, reprints, and investor communications. Advised on CMS Open Payments compliance audits and compliance with the federal Physician Payment Sunshine (Open Payments) law, state laws targeting industry marketing practices, sales representation licensing, drug price transparency, and disclosure of clinical trial data. Advised on compliance with global transparency laws and industry codes of conduct. Advised life sciences clients on preparing for FDA inspections of clinical trials sites and manufacturing facilities, and responding to FDA Form 483s, FDA Warning Letters, product recalls, import detentions, and government investigations involving alleged advertising/promotion violations. Conducted FDA regulatory due diligence and related counseling in connection with more than 200+ transactions involving pharmaceutical, medical device, biotechnology, and cosmetic companies. Stand up healthcare compliance programs for pharmaceutical and medical device manufacturers and related healthcare compliance policies and codes of conduct. Served as interim Chief Compliance Officer for a pharmaceutical manufacturer for a two year period and managed all aspects of the company healthcare compliance program. Conducted internal investigations into potential FDA GCP, GMP, and healthcare compliance policy violations. Led risk assessments of healthcare regulatory compliance programs and policies and advised on compliance with FDA regulations, HHS OIG Compliance Program Guidance, and the PhRMA and AdvaMed Codes on Interactions with Healthcare Professionals.","searchable_name":"Nikki Reeves","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442370,"version":1,"owner_type":"Person","owner_id":880,"payload":{"bio":"\u003cp\u003eJohn Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by\u0026nbsp;President George W. Bush\u0026nbsp;and confirmed by unanimous consent of the U.S. Senate.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;has named\u0026nbsp;John \"White-Collar MVP of the Year\".\u0026nbsp; He also has been\u0026nbsp;recognized as one of the top 100 trial lawyers in America by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;and as a Life Sciences Star for litigation by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e.\u0026nbsp; Most recently, he was elected President of the National Association of Former United States Attorneys.\u003c/p\u003e\n\u003cp\u003eDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President\u0026rsquo;s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\u003c/p\u003e\n\u003cp\u003eAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services\u0026rsquo; Inspector General\u0026rsquo;s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General\u0026rsquo;s Advisory Committee on Sentencing, and as a member of the Attorney General\u0026rsquo;s Advisory Committee on White Collar Crime.\u003c/p\u003e\n\u003cp\u003eJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\u003c/p\u003e\n\u003cp\u003eIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys\u0026rsquo; Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general\u0026rsquo;s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;whistleblower litigation.\u003c/p\u003e\n\u003cp\u003eIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc.,\u0026nbsp;where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;cases.\u003c/p\u003e","slug":"john-richter","email":"jrichter@kslaw.com","phone":null,"matters":["\u003cp\u003eSuccessful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.\u003c/p\u003e","\u003cp\u003eSuccessful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ civil investigation and dismissal of a whistleblower\u0026rsquo;s complaint of publicly traded health insurer based on false claims allegations.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eSuccessful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.\u003c/p\u003e","\u003cp\u003eInvestigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company\u0026rsquo;s computer system and theft of trade secret and proprietary information.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3134}]},"expertise":[{"id":6,"guid":"6.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":6,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":7,"source":"smartTags"},{"id":1303,"guid":"1303.smart_tags","index":8,"source":"smartTags"},{"id":766,"guid":"766.smart_tags","index":9,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":10,"source":"smartTags"},{"id":11,"guid":"11.capabilities","index":11,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":12,"source":"smartTags"},{"id":984,"guid":"984.smart_tags","index":13,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":14,"source":"smartTags"},{"id":1199,"guid":"1199.smart_tags","index":15,"source":"smartTags"},{"id":1248,"guid":"1248.smart_tags","index":16,"source":"smartTags"}],"is_active":true,"last_name":"Richter","nick_name":"John","clerkships":[{"name":"Law Clerk, J. Owen Forrester, U.S. District Court for the Northern District of Georgia","years_held":"1992-1994"}],"first_name":"John","title_rank":9999,"updated_by":202,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1992-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"C.","name_suffix":"","recognitions":[{"title":"“Richter stands out for his significant capabilities as a trial lawyer”","detail":"Legal 500 - 2024"},{"title":"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)","detail":"NAFUSA 2023"},{"title":"Selected,Top 100 Trial Lawyers","detail":"Benchmark Litigation, 2017"},{"title":"Selected, Life Sciences Star","detail":"LMG Life Sciences, 2017"},{"title":"Selected, White Collar Defense MVP","detail":"Law360, 2016"},{"title":"Elected to the Board of Directors, 2017","detail":"National Association of Former United States Attorneys"}],"linked_in_url":null,"seodescription":"John Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group. Find out more about him.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJohn Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by\u0026nbsp;President George W. Bush\u0026nbsp;and confirmed by unanimous consent of the U.S. Senate.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;has named\u0026nbsp;John \"White-Collar MVP of the Year\".\u0026nbsp; He also has been\u0026nbsp;recognized as one of the top 100 trial lawyers in America by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;and as a Life Sciences Star for litigation by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e.\u0026nbsp; Most recently, he was elected President of the National Association of Former United States Attorneys.\u003c/p\u003e\n\u003cp\u003eDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President\u0026rsquo;s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\u003c/p\u003e\n\u003cp\u003eAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services\u0026rsquo; Inspector General\u0026rsquo;s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General\u0026rsquo;s Advisory Committee on Sentencing, and as a member of the Attorney General\u0026rsquo;s Advisory Committee on White Collar Crime.\u003c/p\u003e\n\u003cp\u003eJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\u003c/p\u003e\n\u003cp\u003eIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys\u0026rsquo; Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general\u0026rsquo;s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;whistleblower litigation.\u003c/p\u003e\n\u003cp\u003eIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc.,\u0026nbsp;where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;cases.\u003c/p\u003e","matters":["\u003cp\u003eSuccessful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.\u003c/p\u003e","\u003cp\u003eSuccessful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ civil investigation and dismissal of a whistleblower\u0026rsquo;s complaint of publicly traded health insurer based on false claims allegations.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eSuccessful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.\u003c/p\u003e","\u003cp\u003eInvestigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company\u0026rsquo;s computer system and theft of trade secret and proprietary information.\u003c/p\u003e"],"recognitions":[{"title":"“Richter stands out for his significant capabilities as a trial lawyer”","detail":"Legal 500 - 2024"},{"title":"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)","detail":"NAFUSA 2023"},{"title":"Selected,Top 100 Trial Lawyers","detail":"Benchmark Litigation, 2017"},{"title":"Selected, Life Sciences Star","detail":"LMG Life Sciences, 2017"},{"title":"Selected, White Collar Defense MVP","detail":"Law360, 2016"},{"title":"Elected to the Board of Directors, 2017","detail":"National Association of Former United States Attorneys"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4491}]},"capability_group_id":2},"created_at":"2025-11-05T05:03:40.000Z","updated_at":"2025-11-05T05:03:40.000Z","searchable_text":"Richter{{ FIELD }}{:title=\u0026gt;\"“Richter stands out for his significant capabilities as a trial lawyer”\", :detail=\u0026gt;\"Legal 500 - 2024\"}{{ FIELD }}{:title=\u0026gt;\"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)\", :detail=\u0026gt;\"NAFUSA 2023\"}{{ FIELD }}{:title=\u0026gt;\"Selected,Top 100 Trial Lawyers\", :detail=\u0026gt;\"Benchmark Litigation, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Selected, Life Sciences Star\", :detail=\u0026gt;\"LMG Life Sciences, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Selected, White Collar Defense MVP\", :detail=\u0026gt;\"Law360, 2016\"}{{ FIELD }}{:title=\u0026gt;\"Elected to the Board of Directors, 2017\", :detail=\u0026gt;\"National Association of Former United States Attorneys\"}{{ FIELD }}Successful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.{{ FIELD }}Successful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.{{ FIELD }}Independent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.{{ FIELD }}Successful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.{{ FIELD }}Representation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.{{ FIELD }}Representation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.{{ FIELD }}Successful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.{{ FIELD }}Successful declination of DOJ civil investigation and dismissal of a whistleblower’s complaint of publicly traded health insurer based on false claims allegations.{{ FIELD }}Successful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.{{ FIELD }}Successful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.{{ FIELD }}Independent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.{{ FIELD }}Investigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company’s computer system and theft of trade secret and proprietary information.{{ FIELD }}John Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by President George W. Bush and confirmed by unanimous consent of the U.S. Senate. \nLaw360 has named John \"White-Collar MVP of the Year\".  He also has been recognized as one of the top 100 trial lawyers in America by Benchmark Litigation and as a Life Sciences Star for litigation by LMG Life Sciences.  Most recently, he was elected President of the National Association of Former United States Attorneys.\nDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President’s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\nAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services’ Inspector General’s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General’s Advisory Committee on Sentencing, and as a member of the Attorney General’s Advisory Committee on White Collar Crime.\nJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\nIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys’ Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general’s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or qui tam whistleblower litigation.\nIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc., where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and qui tam cases. john richter Partner “Richter stands out for his significant capabilities as a trial lawyer” Legal 500 - 2024 Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024) NAFUSA 2023 Selected,Top 100 Trial Lawyers Benchmark Litigation, 2017 Selected, Life Sciences Star LMG Life Sciences, 2017 Selected, White Collar Defense MVP Law360, 2016 Elected to the Board of Directors, 2017 National Association of Former United States Attorneys Emory University Emory University School of Law University of Virginia University of Virginia School of Law Supreme Court of the United States U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Western District of Oklahoma U.S. District Court for the Northern District of Georgia District of Columbia Georgia Oklahoma President, National Association of Former United States Attorneys Law Clerk, J. Owen Forrester, U.S. District Court for the Northern District of Georgia Successful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges. Successful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government. Independent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management. Successful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts. Representation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company. Representation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation. Successful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act. Successful declination of DOJ civil investigation and dismissal of a whistleblower’s complaint of publicly traded health insurer based on false claims allegations. Successful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts. Successful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act. Independent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities. Investigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company’s computer system and theft of trade secret and proprietary information.","searchable_name":"John C. Richter","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":445429,"version":1,"owner_type":"Person","owner_id":6187,"payload":{"bio":"\u003cp\u003eA partner in our Finance and Restructuring practice, David Ridenour represents financial institutions as issuers, underwriters, borrowers, lenders, sellers and purchasers in a variety of sophisticated asset-backed securitization and structured lending transactions. \u0026nbsp;In particular, he is an industry leader\u0026nbsp;in the digital infrastructure space, where he serves as issuer\u0026rsquo;s counsel for some of the largest and most active 144A and 4(a)(2) issuance platforms in the market.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDavid also advises lenders and borrowers with respect to senior and mezzanine credit facilities involving unsecured consumer loans, small business loans, mortgage and home equity loans and energy efficiency and solar loans, as well as advising both sellers and purchasers in forward flow purchase arrangements. David has years of experience working on both SEC publicly-registered and privately-negotiated securitization platforms totaling more than $100 billion in issuance value, secured by credit card receivables, franchise loans, timeshare receivables, mortgage servicing rights, automobile loans and leases, equipment loans and leases, mortgage-backed securities and trade receivables.\u003cbr /\u003eChambers USA has ranked David as a Band 4 leading lawyer and noted that he is particularly renowned for his strengths in digital infrastructure ABS mandates. Legal500 similarly highlights David as a key lawyer and emphasizes his prominent work involving cellular towers, fiber networks, and data center securitizations. Additionally, David is a frequent speaker at industry events as an expert in the digital infrastructure space.\u0026nbsp;\u003c/p\u003e","slug":"david-ridenour","email":"dridenour@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eAligned Energy\u003c/strong\u003e\u0026nbsp;\u0026ndash; Advised Aligned on the issuance of $1.35 billion of securitized notes. Largest inaugural data center securitization and first-ever green bond data center securitization.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eStack Infrastructure \u0026ndash;\u0026nbsp;\u003c/strong\u003eHave advised Stack on the issuance of over $1.70 billion of securitized notes. Most recent trade established a record-setting rate for the data center space.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSabey Data Centers\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised Sabey on the issuance of $975 million of securitized notes. Sabey obtained the first-ever A+ rating for a data center securitization.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCompass Data Centers\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised Compass on the issuance of over $850 million of securitized notes.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eLandmark\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised the Landmark and is affiliates on the issuance of $400 million of securitized notes.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":75,"guid":"75.capabilities","index":0,"source":"capabilities"},{"id":82,"guid":"82.capabilities","index":1,"source":"capabilities"},{"id":26,"guid":"26.capabilities","index":2,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":3,"source":"capabilities"},{"id":1434,"guid":"1434.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Ridenour","nick_name":"David","clerkships":[],"first_name":"David","title_rank":9999,"updated_by":35,"law_schools":[{"id":2237,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2005-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"L.","name_suffix":"","recognitions":[{"title":"\"...extremely responsive and dependable, and stand ready to act for the large volume of transaction work at my company.\"","detail":"Legal 500, 2025"},{"title":"\"David is incredibly smart and commercial.\"","detail":"Chambers USA 2025"},{"title":"\"David is a thought leader and trusted counselor.\"","detail":"Chambers USA 2025"},{"title":"\"David has been a great resource for our company and a partner to us on our transactions.\"","detail":"Chambers USA 2025"},{"title":"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide","detail":"Chambers USA 2025"},{"title":"Named Leading Lawyers in America","detail":"Leading Lawyers in America, 2024"},{"title":"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide","detail":"Chambers USA 2024"},{"title":"Rising Star","detail":"IFLR"},{"title":"Recognized","detail":"Legal 500"}],"linked_in_url":"https://www.linkedin.com/in/david-ridenour-623aab45/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in our Finance and Restructuring practice, David Ridenour represents financial institutions as issuers, underwriters, borrowers, lenders, sellers and purchasers in a variety of sophisticated asset-backed securitization and structured lending transactions. \u0026nbsp;In particular, he is an industry leader\u0026nbsp;in the digital infrastructure space, where he serves as issuer\u0026rsquo;s counsel for some of the largest and most active 144A and 4(a)(2) issuance platforms in the market.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDavid also advises lenders and borrowers with respect to senior and mezzanine credit facilities involving unsecured consumer loans, small business loans, mortgage and home equity loans and energy efficiency and solar loans, as well as advising both sellers and purchasers in forward flow purchase arrangements. David has years of experience working on both SEC publicly-registered and privately-negotiated securitization platforms totaling more than $100 billion in issuance value, secured by credit card receivables, franchise loans, timeshare receivables, mortgage servicing rights, automobile loans and leases, equipment loans and leases, mortgage-backed securities and trade receivables.\u003cbr /\u003eChambers USA has ranked David as a Band 4 leading lawyer and noted that he is particularly renowned for his strengths in digital infrastructure ABS mandates. Legal500 similarly highlights David as a key lawyer and emphasizes his prominent work involving cellular towers, fiber networks, and data center securitizations. Additionally, David is a frequent speaker at industry events as an expert in the digital infrastructure space.\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003eAligned Energy\u003c/strong\u003e\u0026nbsp;\u0026ndash; Advised Aligned on the issuance of $1.35 billion of securitized notes. Largest inaugural data center securitization and first-ever green bond data center securitization.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eStack Infrastructure \u0026ndash;\u0026nbsp;\u003c/strong\u003eHave advised Stack on the issuance of over $1.70 billion of securitized notes. Most recent trade established a record-setting rate for the data center space.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSabey Data Centers\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised Sabey on the issuance of $975 million of securitized notes. Sabey obtained the first-ever A+ rating for a data center securitization.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCompass Data Centers\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised Compass on the issuance of over $850 million of securitized notes.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eLandmark\u003c/strong\u003e\u0026nbsp;\u0026ndash; Have advised the Landmark and is affiliates on the issuance of $400 million of securitized notes.\u003c/p\u003e"],"recognitions":[{"title":"\"...extremely responsive and dependable, and stand ready to act for the large volume of transaction work at my company.\"","detail":"Legal 500, 2025"},{"title":"\"David is incredibly smart and commercial.\"","detail":"Chambers USA 2025"},{"title":"\"David is a thought leader and trusted counselor.\"","detail":"Chambers USA 2025"},{"title":"\"David has been a great resource for our company and a partner to us on our transactions.\"","detail":"Chambers USA 2025"},{"title":"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide","detail":"Chambers USA 2025"},{"title":"Named Leading Lawyers in America","detail":"Leading Lawyers in America, 2024"},{"title":"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide","detail":"Chambers USA 2024"},{"title":"Rising Star","detail":"IFLR"},{"title":"Recognized","detail":"Legal 500"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9357}]},"capability_group_id":1},"created_at":"2026-01-30T22:02:18.000Z","updated_at":"2026-01-30T22:02:18.000Z","searchable_text":"Ridenour{{ FIELD }}{:title=\u0026gt;\"\\\"...extremely responsive and dependable, and stand ready to act for the large volume of transaction work at my company.\\\"\", :detail=\u0026gt;\"Legal 500, 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"David is incredibly smart and commercial.\\\"\", :detail=\u0026gt;\"Chambers USA 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"David is a thought leader and trusted counselor.\\\"\", :detail=\u0026gt;\"Chambers USA 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"David has been a great resource for our company and a partner to us on our transactions.\\\"\", :detail=\u0026gt;\"Chambers USA 2025\"}{{ FIELD }}{:title=\u0026gt;\"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide\", :detail=\u0026gt;\"Chambers USA 2025\"}{{ FIELD }}{:title=\u0026gt;\"Named Leading Lawyers in America\", :detail=\u0026gt;\"Leading Lawyers in America, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide\", :detail=\u0026gt;\"Chambers USA 2024\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star\", :detail=\u0026gt;\"IFLR\"}{{ FIELD }}{:title=\u0026gt;\"Recognized\", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}Aligned Energy – Advised Aligned on the issuance of $1.35 billion of securitized notes. Largest inaugural data center securitization and first-ever green bond data center securitization.{{ FIELD }}Stack Infrastructure – Have advised Stack on the issuance of over $1.70 billion of securitized notes. Most recent trade established a record-setting rate for the data center space.{{ FIELD }}Sabey Data Centers – Have advised Sabey on the issuance of $975 million of securitized notes. Sabey obtained the first-ever A+ rating for a data center securitization.{{ FIELD }}Compass Data Centers – Have advised Compass on the issuance of over $850 million of securitized notes.{{ FIELD }}Landmark – Have advised the Landmark and is affiliates on the issuance of $400 million of securitized notes.{{ FIELD }}A partner in our Finance and Restructuring practice, David Ridenour represents financial institutions as issuers, underwriters, borrowers, lenders, sellers and purchasers in a variety of sophisticated asset-backed securitization and structured lending transactions.  In particular, he is an industry leader in the digital infrastructure space, where he serves as issuer’s counsel for some of the largest and most active 144A and 4(a)(2) issuance platforms in the market.\nDavid also advises lenders and borrowers with respect to senior and mezzanine credit facilities involving unsecured consumer loans, small business loans, mortgage and home equity loans and energy efficiency and solar loans, as well as advising both sellers and purchasers in forward flow purchase arrangements. David has years of experience working on both SEC publicly-registered and privately-negotiated securitization platforms totaling more than $100 billion in issuance value, secured by credit card receivables, franchise loans, timeshare receivables, mortgage servicing rights, automobile loans and leases, equipment loans and leases, mortgage-backed securities and trade receivables.Chambers USA has ranked David as a Band 4 leading lawyer and noted that he is particularly renowned for his strengths in digital infrastructure ABS mandates. Legal500 similarly highlights David as a key lawyer and emphasizes his prominent work involving cellular towers, fiber networks, and data center securitizations. Additionally, David is a frequent speaker at industry events as an expert in the digital infrastructure space.  Partner \"...extremely responsive and dependable, and stand ready to act for the large volume of transaction work at my company.\" Legal 500, 2025 \"David is incredibly smart and commercial.\" Chambers USA 2025 \"David is a thought leader and trusted counselor.\" Chambers USA 2025 \"David has been a great resource for our company and a partner to us on our transactions.\" Chambers USA 2025 Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide Chambers USA 2025 Named Leading Lawyers in America Leading Lawyers in America, 2024 Top ranked - Band 4 lawyer, Capital Markets: Securitization: ABS-USA-Nationwide Chambers USA 2024 Rising Star IFLR Recognized Legal 500 University of Nebraska at Lincoln Lincoln College of Law University of Michigan University of Michigan Law School District of Columbia Texas Virginia Aligned Energy – Advised Aligned on the issuance of $1.35 billion of securitized notes. Largest inaugural data center securitization and first-ever green bond data center securitization. Stack Infrastructure – Have advised Stack on the issuance of over $1.70 billion of securitized notes. Most recent trade established a record-setting rate for the data center space. Sabey Data Centers – Have advised Sabey on the issuance of $975 million of securitized notes. Sabey obtained the first-ever A+ rating for a data center securitization. Compass Data Centers – Have advised Compass on the issuance of over $850 million of securitized notes. Landmark – Have advised the Landmark and is affiliates on the issuance of $400 million of securitized notes.","searchable_name":"David L. Ridenour","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":426281,"version":1,"owner_type":"Person","owner_id":2105,"payload":{"bio":"\u003cp\u003eJessica Ringel advises\u0026nbsp;medical device, pharmaceutical, HCT/P, and cosmetics manufacturers\u0026nbsp;and distributors\u0026nbsp;on matters involving FDA regulation. Jessica\u0026rsquo;s post-market practice focuses on safety and quality matters, including responses to FDA inspections and enforcement actions, recall and adverse event matters, and advertising and promotion. Her pre-market practice includes advising on regulatory strategy and marketing applications. Jessica\u0026rsquo;s transactional practice involves conducting due diligence evaluations of life sciences targets for manufacturers, private equity firms, and investment banks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica\u0026rsquo;s device regulatory practice spans the entire FDA regulatory lifecycle.\u0026nbsp; She advises clients on premarket regulatory strategy by assessing pathways to market, identifying predicate devices for 510(k) submissions, preparing q-submissions to receive FDA feedback, and assisting clients with the preparation and submission of marketing applications, including 510(k)s, De Novos, and PMAs.\u0026nbsp; After clearance or approval of a device, Jessica advises clients on the full range of post-market compliance matters.\u0026nbsp; She assists firms in preparing for and managing FDA inspections, responding to FDA-483s and Warning Letters, and implementing quality system corrective actions and remediation plans.\u0026nbsp; Jessica also advises clients on product recall strategy and communications and adverse event reporting obligations.\u0026nbsp; She further assists life sciences clients with the review and development of compliant marketing strategies and materials.\u0026nbsp; She assists clients with FDA-related import matters, including by responding to import detentions to obtain the release of products held by FDA.\u0026nbsp; Jessica also advises companies that process and distribute human tissue-based products (HCT/Ps) and that manufacture and distribute electronic products subject to FDA\u0026rsquo;s electronic product radiation control program. Further, Jessica has also worked with multiple clients on the negotiation of, and operations under, consent decrees of injunction with FDA. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJessica\u0026rsquo;s regulatory practice is supplemented by extensive experience conducting FDA regulatory due diligence evaluations of life sciences targets, assessing the regulatory compliance history, health, and risk of the target company.\u0026nbsp; She further advises corporate transaction teams and clients by preparing and negotiating terms and provisions in purchase agreements related to FDA regulatory compliance.\u003c/p\u003e","slug":"jessica-ringel","email":"jringel@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":3,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":4,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"Ringel","nick_name":"Jessica","clerkships":[],"first_name":"Jessica","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJessica Ringel advises\u0026nbsp;medical device, pharmaceutical, HCT/P, and cosmetics manufacturers\u0026nbsp;and distributors\u0026nbsp;on matters involving FDA regulation. Jessica\u0026rsquo;s post-market practice focuses on safety and quality matters, including responses to FDA inspections and enforcement actions, recall and adverse event matters, and advertising and promotion. Her pre-market practice includes advising on regulatory strategy and marketing applications. Jessica\u0026rsquo;s transactional practice involves conducting due diligence evaluations of life sciences targets for manufacturers, private equity firms, and investment banks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica\u0026rsquo;s device regulatory practice spans the entire FDA regulatory lifecycle.\u0026nbsp; She advises clients on premarket regulatory strategy by assessing pathways to market, identifying predicate devices for 510(k) submissions, preparing q-submissions to receive FDA feedback, and assisting clients with the preparation and submission of marketing applications, including 510(k)s, De Novos, and PMAs.\u0026nbsp; After clearance or approval of a device, Jessica advises clients on the full range of post-market compliance matters.\u0026nbsp; She assists firms in preparing for and managing FDA inspections, responding to FDA-483s and Warning Letters, and implementing quality system corrective actions and remediation plans.\u0026nbsp; Jessica also advises clients on product recall strategy and communications and adverse event reporting obligations.\u0026nbsp; She further assists life sciences clients with the review and development of compliant marketing strategies and materials.\u0026nbsp; She assists clients with FDA-related import matters, including by responding to import detentions to obtain the release of products held by FDA.\u0026nbsp; Jessica also advises companies that process and distribute human tissue-based products (HCT/Ps) and that manufacture and distribute electronic products subject to FDA\u0026rsquo;s electronic product radiation control program. Further, Jessica has also worked with multiple clients on the negotiation of, and operations under, consent decrees of injunction with FDA. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJessica\u0026rsquo;s regulatory practice is supplemented by extensive experience conducting FDA regulatory due diligence evaluations of life sciences targets, assessing the regulatory compliance history, health, and risk of the target company.\u0026nbsp; She further advises corporate transaction teams and clients by preparing and negotiating terms and provisions in purchase agreements related to FDA regulatory compliance.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1146}]},"capability_group_id":2},"created_at":"2025-05-26T04:50:06.000Z","updated_at":"2025-05-26T04:50:06.000Z","searchable_text":"Ringel{{ FIELD }}Jessica Ringel advises medical device, pharmaceutical, HCT/P, and cosmetics manufacturers and distributors on matters involving FDA regulation. Jessica’s post-market practice focuses on safety and quality matters, including responses to FDA inspections and enforcement actions, recall and adverse event matters, and advertising and promotion. Her pre-market practice includes advising on regulatory strategy and marketing applications. Jessica’s transactional practice involves conducting due diligence evaluations of life sciences targets for manufacturers, private equity firms, and investment banks.\nJessica’s device regulatory practice spans the entire FDA regulatory lifecycle.  She advises clients on premarket regulatory strategy by assessing pathways to market, identifying predicate devices for 510(k) submissions, preparing q-submissions to receive FDA feedback, and assisting clients with the preparation and submission of marketing applications, including 510(k)s, De Novos, and PMAs.  After clearance or approval of a device, Jessica advises clients on the full range of post-market compliance matters.  She assists firms in preparing for and managing FDA inspections, responding to FDA-483s and Warning Letters, and implementing quality system corrective actions and remediation plans.  Jessica also advises clients on product recall strategy and communications and adverse event reporting obligations.  She further assists life sciences clients with the review and development of compliant marketing strategies and materials.  She assists clients with FDA-related import matters, including by responding to import detentions to obtain the release of products held by FDA.  Jessica also advises companies that process and distribute human tissue-based products (HCT/Ps) and that manufacture and distribute electronic products subject to FDA’s electronic product radiation control program. Further, Jessica has also worked with multiple clients on the negotiation of, and operations under, consent decrees of injunction with FDA.   \nJessica’s regulatory practice is supplemented by extensive experience conducting FDA regulatory due diligence evaluations of life sciences targets, assessing the regulatory compliance history, health, and risk of the target company.  She further advises corporate transaction teams and clients by preparing and negotiating terms and provisions in purchase agreements related to FDA regulatory compliance. Partner Cornell University Cornell Law School Georgetown University Georgetown University Law Center District of Columbia Maryland","searchable_name":"Jessica Ringel","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":447488,"version":1,"owner_type":"Person","owner_id":6483,"payload":{"bio":"\u003cp\u003eJeffrey S. Rosenberg is a trial litigator whose practice focuses on complex business and commercial litigation, with an emphasis on securities, shareholder, M\u0026amp;A, and Delaware litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg defends a broad spectrum of commercial litigation and has extensive experience representing\u0026nbsp;companies and their officers and directors in shareholder disputes such as securities class actions, derivative lawsuits alleging breaches of fiduciary duties, challenges to mergers and acquisitions, and books and records demands.\u0026nbsp; He also advises boards of directors and their committees in conducting internal investigations and evaluating and responding to shareholder demands.\u0026nbsp; He further represents companies in litigation and enforcement actions involving the government, principally in the securities and financial sectors.\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg has been recognized in the \u003cem\u003eLawdragon 500 Leading Litigators in America\u003c/em\u003e\u0026nbsp;for his work in \"Business \u0026amp; Commercial Litigation, esp. Delaware\"\u0026nbsp;and\u0026nbsp;in\u0026nbsp;\u003cem\u003eBest Lawyers: Ones to Watch\u003c/em\u003e\u0026nbsp;in multiple practice areas.\u0026nbsp; He regularly publishes on developments in Delaware law and has co-authored treatise chapters on securities, derivative, and Delaware litigation.\u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg is a\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;graduate of the Georgetown University Law Center.\u0026nbsp; He received a Bachelor of Arts degree, with honors, from Johns Hopkins University with a double major in Classics and Philosophy.\u0026nbsp; While an undergraduate, he concurrently completed and graduated with a Master of Arts degree in Classics.\u003c/p\u003e\n\u003cp\u003eWhile pursuing his law degree, Mr. Rosenberg worked as a consultant providing homeland security, critical infrastructure protection, incident and emergency management, strategic and operational policy and planning, and enterprise risk management advice to public and private sector clients.\u003c/p\u003e","slug":"jeffrey-rosenberg","email":"jrosenberg@kslaw.com","phone":"","matters":["\u003cp\u003eWon dismissal of a securities class action, which was affirmed on appeal, and two parallel derivative actions claiming\u0026nbsp;\u003cstrong\u003eMarriott\u003c/strong\u003e\u0026nbsp;made false and misleading statements concerning its susceptibility to cyberattacks.\u003c/p\u003e","\u003cp\u003eWon dismissal of a securities class action alleging\u0026nbsp;\u003cstrong\u003eProgenity\u0026nbsp;\u003c/strong\u003e(now\u0026nbsp;\u003cstrong\u003eBiora\u003c/strong\u003e), a biotechnology developer and provider of testing products, made false statements in its offering documents under Section 11.\u003c/p\u003e","\u003cp\u003eWon dismissal of a securities class action assailing\u0026nbsp;\u003cstrong\u003eNorthwest Biotherapeutics'\u003c/strong\u003e\u0026nbsp;public statements about the development of its products.\u003c/p\u003e","\u003cp\u003eRepresented four members of the evenly divided board of directors of\u0026nbsp;\u003cstrong\u003eAerojet Rocketdyne\u003c/strong\u003e\u0026nbsp;in an expedited trial before the Delaware Court of Chancery arising from a proxy contest initiated by the company\u0026rsquo;s executive chairman. The clients prevailed in the proxy contest after the court issued its post-trial opinion.\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003eBlackRock\u003c/strong\u003e\u0026nbsp;in suit in the Virgin Islands brought by shareholders of two public companies alleging that BlackRock fraudulently drove down the share price of the companies.\u003c/p\u003e","\u003cp\u003eRepresenting current and former directors, officers, and investors of\u0026nbsp;\u003cstrong\u003eGerald Metals\u003c/strong\u003e, the largest privately owned metals trading firm in the world, in litigation brought by former senior executives and shareholders.\u003c/p\u003e","\u003cp\u003eDefended\u0026nbsp;\u003cstrong\u003eBank of America\u0026nbsp;\u003c/strong\u003eagainst FDIC lawsuit seeking alleged underpayment to the Federal Deposit Insurance Fund of more than $1 billion and asserting counterclaim under the Administrative Procedure Act seeking to invalidate the underlying FDIC regulation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eKraft Heinz\u003c/strong\u003e\u0026nbsp;in negotiating successful resolution of accounting fraud claims brought by the SEC with no criminal component, substantially reduced financial penalty, and non-scienter-based charges.\u003c/p\u003e","\u003cp\u003eDefended the largest shareholder and certain current and former directors of an aerospace company in derivative litigation brought by minority shareholders and directors in the Delaware Court of Chancery. Argued the dispositive motion.\u003c/p\u003e","\u003cp\u003eObtained complete arbitration victory, including all costs, for asset management company regarding its significant equity stake in a hedge fund whose principals sought to forcibly transfer that stake away from client.\u003c/p\u003e","\u003cp\u003eObtained complete arbitration victory for major multinational company in intra- and inter-corporate dispute involving\u0026nbsp;significant subsidiary.\u003c/p\u003e","\u003cp\u003eRepresented petitioners in appraisal litigation involving a biotechnology company in the Delaware Court of Chancery resulting in favorable settlement.\u003c/p\u003e","\u003cp\u003eDefended a biotechnology company in a series of shareholder derivative lawsuits challenging the decisions of company directors and executives, leading to favorable settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully litigated motion to sever and stay indicted healthcare fraud prosecution based on client\u0026rsquo;s physical incapacity, leading to complete dismissal of indictment.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3463}]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":1,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":2,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":3,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":4,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":126,"guid":"126.capabilities","index":7,"source":"capabilities"},{"id":1248,"guid":"1248.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Rosenberg","nick_name":"Jeff","clerkships":[],"first_name":"Jeffrey","title_rank":9999,"updated_by":202,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2012-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"S.","name_suffix":"","recognitions":[{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2024, 2025, 2026"},{"title":"Ones to Watch in America","detail":"Best Lawyers, 2023, 2024, 2025"}],"linked_in_url":"https://www.linkedin.com/in/rosenbergjeffrey/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJeffrey S. Rosenberg is a trial litigator whose practice focuses on complex business and commercial litigation, with an emphasis on securities, shareholder, M\u0026amp;A, and Delaware litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg defends a broad spectrum of commercial litigation and has extensive experience representing\u0026nbsp;companies and their officers and directors in shareholder disputes such as securities class actions, derivative lawsuits alleging breaches of fiduciary duties, challenges to mergers and acquisitions, and books and records demands.\u0026nbsp; He also advises boards of directors and their committees in conducting internal investigations and evaluating and responding to shareholder demands.\u0026nbsp; He further represents companies in litigation and enforcement actions involving the government, principally in the securities and financial sectors.\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg has been recognized in the \u003cem\u003eLawdragon 500 Leading Litigators in America\u003c/em\u003e\u0026nbsp;for his work in \"Business \u0026amp; Commercial Litigation, esp. Delaware\"\u0026nbsp;and\u0026nbsp;in\u0026nbsp;\u003cem\u003eBest Lawyers: Ones to Watch\u003c/em\u003e\u0026nbsp;in multiple practice areas.\u0026nbsp; He regularly publishes on developments in Delaware law and has co-authored treatise chapters on securities, derivative, and Delaware litigation.\u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMr. Rosenberg is a\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;graduate of the Georgetown University Law Center.\u0026nbsp; He received a Bachelor of Arts degree, with honors, from Johns Hopkins University with a double major in Classics and Philosophy.\u0026nbsp; While an undergraduate, he concurrently completed and graduated with a Master of Arts degree in Classics.\u003c/p\u003e\n\u003cp\u003eWhile pursuing his law degree, Mr. Rosenberg worked as a consultant providing homeland security, critical infrastructure protection, incident and emergency management, strategic and operational policy and planning, and enterprise risk management advice to public and private sector clients.\u003c/p\u003e","matters":["\u003cp\u003eWon dismissal of a securities class action, which was affirmed on appeal, and two parallel derivative actions claiming\u0026nbsp;\u003cstrong\u003eMarriott\u003c/strong\u003e\u0026nbsp;made false and misleading statements concerning its susceptibility to cyberattacks.\u003c/p\u003e","\u003cp\u003eWon dismissal of a securities class action alleging\u0026nbsp;\u003cstrong\u003eProgenity\u0026nbsp;\u003c/strong\u003e(now\u0026nbsp;\u003cstrong\u003eBiora\u003c/strong\u003e), a biotechnology developer and provider of testing products, made false statements in its offering documents under Section 11.\u003c/p\u003e","\u003cp\u003eWon dismissal of a securities class action assailing\u0026nbsp;\u003cstrong\u003eNorthwest Biotherapeutics'\u003c/strong\u003e\u0026nbsp;public statements about the development of its products.\u003c/p\u003e","\u003cp\u003eRepresented four members of the evenly divided board of directors of\u0026nbsp;\u003cstrong\u003eAerojet Rocketdyne\u003c/strong\u003e\u0026nbsp;in an expedited trial before the Delaware Court of Chancery arising from a proxy contest initiated by the company\u0026rsquo;s executive chairman. The clients prevailed in the proxy contest after the court issued its post-trial opinion.\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003eBlackRock\u003c/strong\u003e\u0026nbsp;in suit in the Virgin Islands brought by shareholders of two public companies alleging that BlackRock fraudulently drove down the share price of the companies.\u003c/p\u003e","\u003cp\u003eRepresenting current and former directors, officers, and investors of\u0026nbsp;\u003cstrong\u003eGerald Metals\u003c/strong\u003e, the largest privately owned metals trading firm in the world, in litigation brought by former senior executives and shareholders.\u003c/p\u003e","\u003cp\u003eDefended\u0026nbsp;\u003cstrong\u003eBank of America\u0026nbsp;\u003c/strong\u003eagainst FDIC lawsuit seeking alleged underpayment to the Federal Deposit Insurance Fund of more than $1 billion and asserting counterclaim under the Administrative Procedure Act seeking to invalidate the underlying FDIC regulation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003eKraft Heinz\u003c/strong\u003e\u0026nbsp;in negotiating successful resolution of accounting fraud claims brought by the SEC with no criminal component, substantially reduced financial penalty, and non-scienter-based charges.\u003c/p\u003e","\u003cp\u003eDefended the largest shareholder and certain current and former directors of an aerospace company in derivative litigation brought by minority shareholders and directors in the Delaware Court of Chancery. Argued the dispositive motion.\u003c/p\u003e","\u003cp\u003eObtained complete arbitration victory, including all costs, for asset management company regarding its significant equity stake in a hedge fund whose principals sought to forcibly transfer that stake away from client.\u003c/p\u003e","\u003cp\u003eObtained complete arbitration victory for major multinational company in intra- and inter-corporate dispute involving\u0026nbsp;significant subsidiary.\u003c/p\u003e","\u003cp\u003eRepresented petitioners in appraisal litigation involving a biotechnology company in the Delaware Court of Chancery resulting in favorable settlement.\u003c/p\u003e","\u003cp\u003eDefended a biotechnology company in a series of shareholder derivative lawsuits challenging the decisions of company directors and executives, leading to favorable settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully litigated motion to sever and stay indicted healthcare fraud prosecution based on client\u0026rsquo;s physical incapacity, leading to complete dismissal of indictment.\u003c/p\u003e"],"recognitions":[{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2024, 2025, 2026"},{"title":"Ones to Watch in America","detail":"Best Lawyers, 2023, 2024, 2025"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10807}]},"capability_group_id":3},"created_at":"2026-04-13T16:07:48.000Z","updated_at":"2026-04-13T16:07:48.000Z","searchable_text":"Rosenberg{{ FIELD }}{:title=\u0026gt;\"500 Leading Litigators in America\", :detail=\u0026gt;\"Lawdragon, 2024, 2025, 2026\"}{{ FIELD }}{:title=\u0026gt;\"Ones to Watch in America\", :detail=\u0026gt;\"Best Lawyers, 2023, 2024, 2025\"}{{ FIELD }}Won dismissal of a securities class action, which was affirmed on appeal, and two parallel derivative actions claiming Marriott made false and misleading statements concerning its susceptibility to cyberattacks.{{ FIELD }}Won dismissal of a securities class action alleging Progenity (now Biora), a biotechnology developer and provider of testing products, made false statements in its offering documents under Section 11.{{ FIELD }}Won dismissal of a securities class action assailing Northwest Biotherapeutics' public statements about the development of its products.{{ FIELD }}Represented four members of the evenly divided board of directors of Aerojet Rocketdyne in an expedited trial before the Delaware Court of Chancery arising from a proxy contest initiated by the company’s executive chairman. The clients prevailed in the proxy contest after the court issued its post-trial opinion.{{ FIELD }}Defending BlackRock in suit in the Virgin Islands brought by shareholders of two public companies alleging that BlackRock fraudulently drove down the share price of the companies.{{ FIELD }}Representing current and former directors, officers, and investors of Gerald Metals, the largest privately owned metals trading firm in the world, in litigation brought by former senior executives and shareholders.{{ FIELD }}Defended Bank of America against FDIC lawsuit seeking alleged underpayment to the Federal Deposit Insurance Fund of more than $1 billion and asserting counterclaim under the Administrative Procedure Act seeking to invalidate the underlying FDIC regulation.{{ FIELD }}Represented Kraft Heinz in negotiating successful resolution of accounting fraud claims brought by the SEC with no criminal component, substantially reduced financial penalty, and non-scienter-based charges.{{ FIELD }}Defended the largest shareholder and certain current and former directors of an aerospace company in derivative litigation brought by minority shareholders and directors in the Delaware Court of Chancery. Argued the dispositive motion.{{ FIELD }}Obtained complete arbitration victory, including all costs, for asset management company regarding its significant equity stake in a hedge fund whose principals sought to forcibly transfer that stake away from client.{{ FIELD }}Obtained complete arbitration victory for major multinational company in intra- and inter-corporate dispute involving significant subsidiary.{{ FIELD }}Represented petitioners in appraisal litigation involving a biotechnology company in the Delaware Court of Chancery resulting in favorable settlement.{{ FIELD }}Defended a biotechnology company in a series of shareholder derivative lawsuits challenging the decisions of company directors and executives, leading to favorable settlement.{{ FIELD }}Successfully litigated motion to sever and stay indicted healthcare fraud prosecution based on client’s physical incapacity, leading to complete dismissal of indictment.{{ FIELD }}Jeffrey S. Rosenberg is a trial litigator whose practice focuses on complex business and commercial litigation, with an emphasis on securities, shareholder, M\u0026amp;A, and Delaware litigation. \nMr. Rosenberg defends a broad spectrum of commercial litigation and has extensive experience representing companies and their officers and directors in shareholder disputes such as securities class actions, derivative lawsuits alleging breaches of fiduciary duties, challenges to mergers and acquisitions, and books and records demands.  He also advises boards of directors and their committees in conducting internal investigations and evaluating and responding to shareholder demands.  He further represents companies in litigation and enforcement actions involving the government, principally in the securities and financial sectors.\nMr. Rosenberg has been recognized in the Lawdragon 500 Leading Litigators in America for his work in \"Business \u0026amp; Commercial Litigation, esp. Delaware\" and in Best Lawyers: Ones to Watch in multiple practice areas.  He regularly publishes on developments in Delaware law and has co-authored treatise chapters on securities, derivative, and Delaware litigation.    \nMr. Rosenberg is a cum laude graduate of the Georgetown University Law Center.  He received a Bachelor of Arts degree, with honors, from Johns Hopkins University with a double major in Classics and Philosophy.  While an undergraduate, he concurrently completed and graduated with a Master of Arts degree in Classics.\nWhile pursuing his law degree, Mr. Rosenberg worked as a consultant providing homeland security, critical infrastructure protection, incident and emergency management, strategic and operational policy and planning, and enterprise risk management advice to public and private sector clients. Jeffrey Rosenberg lawyer Partner 500 Leading Litigators in America Lawdragon, 2024, 2025, 2026 Ones to Watch in America Best Lawyers, 2023, 2024, 2025 Johns Hopkins University  Georgetown University Georgetown University Law Center Johns Hopkins University  U.S. Court of Appeals for the Fourth Circuit U.S. District Court for the District of Maryland U.S. District Court for the Eastern District of Virginia U.S. District Court for the Western District of Virginia U.S. District Court for the District of Columbia District of Columbia New York Virginia Won dismissal of a securities class action, which was affirmed on appeal, and two parallel derivative actions claiming Marriott made false and misleading statements concerning its susceptibility to cyberattacks. Won dismissal of a securities class action alleging Progenity (now Biora), a biotechnology developer and provider of testing products, made false statements in its offering documents under Section 11. Won dismissal of a securities class action assailing Northwest Biotherapeutics' public statements about the development of its products. Represented four members of the evenly divided board of directors of Aerojet Rocketdyne in an expedited trial before the Delaware Court of Chancery arising from a proxy contest initiated by the company’s executive chairman. The clients prevailed in the proxy contest after the court issued its post-trial opinion. Defending BlackRock in suit in the Virgin Islands brought by shareholders of two public companies alleging that BlackRock fraudulently drove down the share price of the companies. Representing current and former directors, officers, and investors of Gerald Metals, the largest privately owned metals trading firm in the world, in litigation brought by former senior executives and shareholders. Defended Bank of America against FDIC lawsuit seeking alleged underpayment to the Federal Deposit Insurance Fund of more than $1 billion and asserting counterclaim under the Administrative Procedure Act seeking to invalidate the underlying FDIC regulation. Represented Kraft Heinz in negotiating successful resolution of accounting fraud claims brought by the SEC with no criminal component, substantially reduced financial penalty, and non-scienter-based charges. Defended the largest shareholder and certain current and former directors of an aerospace company in derivative litigation brought by minority shareholders and directors in the Delaware Court of Chancery. Argued the dispositive motion. Obtained complete arbitration victory, including all costs, for asset management company regarding its significant equity stake in a hedge fund whose principals sought to forcibly transfer that stake away from client. Obtained complete arbitration victory for major multinational company in intra- and inter-corporate dispute involving significant subsidiary. Represented petitioners in appraisal litigation involving a biotechnology company in the Delaware Court of Chancery resulting in favorable settlement. Defended a biotechnology company in a series of shareholder derivative lawsuits challenging the decisions of company directors and executives, leading to favorable settlement. Successfully litigated motion to sever and stay indicted healthcare fraud prosecution based on client’s physical incapacity, leading to complete dismissal of indictment.","searchable_name":"Jeffrey S. Rosenberg (Jeff)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":443985,"version":1,"owner_type":"Person","owner_id":6913,"payload":{"bio":"\u003cp\u003eAs a partner in our FDA and Life Sciences practice, Lauren leverages nearly two decades of experience in legal practice and senior roles at the FDA to advise clients on legal, regulatory, and compliance matters across FDA-regulated industries. Most recently, as FDA\u0026rsquo;s Associate Commissioner for Policy, Lauren played a key role in all major policy initiatives. Lauren translates her experience to help clients navigate the complex issues facing their businesses at the intersections of law, science, and policy.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLauren brings a breadth of experience advising senior public officials and life sciences companies on legal, regulatory, and policy matters. As the Associate Commissioner for Policy from 2019-2024, Lauren led the Commissioner\u0026rsquo;s Office of Policy (OP), supervising issuance of all FDA regulations and guidance documents. She advised agency, HHS, and Administration officials on high priority and novel matters, including implementation of new authorities for drugs, devices, food, and cosmetics. She also served as FDA\u0026rsquo;s lead negotiator for the fifth medical device user fee agreement, playing a pivotal role in shaping current policies and practices related to premarket review, digital health, patient engagement, and use of real-world evidence.\u003c/p\u003e\n\u003cp\u003ePreviously, Lauren was a Senior Advisor to FDA\u0026rsquo;s Chief of Staff (2017-2019) and the Associate Director for Strategy and Regulatory Operations within the Center for Devices and Radiological Health (2016-2017). In those roles, she advised on regulatory, legislative, and compliance matters, including strategic initiatives on device safety and tobacco product regulation.\u003c/p\u003e\n\u003cp\u003eBefore joining FDA, Lauren served as Assistant General Counsel to an association of the United States\u0026rsquo;s leading manufacturers of innovative pharmaceutical products, Pharmaceutical Research and Manufacturers of America (PhRMA). She advised the association on issues related to government enforcement of healthcare fraud and abuse laws, corporate compliance programs, patient adherence and access programs, and drug distribution channels.\u003c/p\u003e\n\u003cp\u003eIn private practice, Lauren advised companies on compliance with healthcare regulations, including the Federal Food, Drug, and Cosmetic Act; the False Claims Act; the anti-kickback statute; and exclusion and debarment laws. She also guided healthcare companies in government investigations (criminal and civil) and conducted internal investigations to analyze legal risk and compliance issues.\u003c/p\u003e\n\u003cp\u003eLauren earned her J.D. from the University of Virginia, where she served as an Articles Editor for the\u003cem\u003e Virginia Law Review.\u003c/em\u003e\u003c/p\u003e","slug":"lauren-roth","email":"lroth@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":2,"source":"capabilities"},{"id":133,"guid":"133.capabilities","index":3,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":4,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"Roth","nick_name":"Lauren","clerkships":[],"first_name":"Lauren","title_rank":9999,"updated_by":35,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2007-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"FDA Award of Merit","detail":"2023"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAs a partner in our FDA and Life Sciences practice, Lauren leverages nearly two decades of experience in legal practice and senior roles at the FDA to advise clients on legal, regulatory, and compliance matters across FDA-regulated industries. Most recently, as FDA\u0026rsquo;s Associate Commissioner for Policy, Lauren played a key role in all major policy initiatives. Lauren translates her experience to help clients navigate the complex issues facing their businesses at the intersections of law, science, and policy.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eLauren brings a breadth of experience advising senior public officials and life sciences companies on legal, regulatory, and policy matters. As the Associate Commissioner for Policy from 2019-2024, Lauren led the Commissioner\u0026rsquo;s Office of Policy (OP), supervising issuance of all FDA regulations and guidance documents. She advised agency, HHS, and Administration officials on high priority and novel matters, including implementation of new authorities for drugs, devices, food, and cosmetics. She also served as FDA\u0026rsquo;s lead negotiator for the fifth medical device user fee agreement, playing a pivotal role in shaping current policies and practices related to premarket review, digital health, patient engagement, and use of real-world evidence.\u003c/p\u003e\n\u003cp\u003ePreviously, Lauren was a Senior Advisor to FDA\u0026rsquo;s Chief of Staff (2017-2019) and the Associate Director for Strategy and Regulatory Operations within the Center for Devices and Radiological Health (2016-2017). In those roles, she advised on regulatory, legislative, and compliance matters, including strategic initiatives on device safety and tobacco product regulation.\u003c/p\u003e\n\u003cp\u003eBefore joining FDA, Lauren served as Assistant General Counsel to an association of the United States\u0026rsquo;s leading manufacturers of innovative pharmaceutical products, Pharmaceutical Research and Manufacturers of America (PhRMA). She advised the association on issues related to government enforcement of healthcare fraud and abuse laws, corporate compliance programs, patient adherence and access programs, and drug distribution channels.\u003c/p\u003e\n\u003cp\u003eIn private practice, Lauren advised companies on compliance with healthcare regulations, including the Federal Food, Drug, and Cosmetic Act; the False Claims Act; the anti-kickback statute; and exclusion and debarment laws. She also guided healthcare companies in government investigations (criminal and civil) and conducted internal investigations to analyze legal risk and compliance issues.\u003c/p\u003e\n\u003cp\u003eLauren earned her J.D. from the University of Virginia, where she served as an Articles Editor for the\u003cem\u003e Virginia Law Review.\u003c/em\u003e\u003c/p\u003e","recognitions":[{"title":"FDA Award of Merit","detail":"2023"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12437}]},"capability_group_id":2},"created_at":"2025-12-05T05:02:19.000Z","updated_at":"2025-12-05T05:02:19.000Z","searchable_text":"Roth{{ FIELD }}{:title=\u0026gt;\"FDA Award of Merit\", :detail=\u0026gt;\"2023\"}{{ FIELD }}As a partner in our FDA and Life Sciences practice, Lauren leverages nearly two decades of experience in legal practice and senior roles at the FDA to advise clients on legal, regulatory, and compliance matters across FDA-regulated industries. Most recently, as FDA’s Associate Commissioner for Policy, Lauren played a key role in all major policy initiatives. Lauren translates her experience to help clients navigate the complex issues facing their businesses at the intersections of law, science, and policy.\nLauren brings a breadth of experience advising senior public officials and life sciences companies on legal, regulatory, and policy matters. As the Associate Commissioner for Policy from 2019-2024, Lauren led the Commissioner’s Office of Policy (OP), supervising issuance of all FDA regulations and guidance documents. She advised agency, HHS, and Administration officials on high priority and novel matters, including implementation of new authorities for drugs, devices, food, and cosmetics. She also served as FDA’s lead negotiator for the fifth medical device user fee agreement, playing a pivotal role in shaping current policies and practices related to premarket review, digital health, patient engagement, and use of real-world evidence.\nPreviously, Lauren was a Senior Advisor to FDA’s Chief of Staff (2017-2019) and the Associate Director for Strategy and Regulatory Operations within the Center for Devices and Radiological Health (2016-2017). In those roles, she advised on regulatory, legislative, and compliance matters, including strategic initiatives on device safety and tobacco product regulation.\nBefore joining FDA, Lauren served as Assistant General Counsel to an association of the United States’s leading manufacturers of innovative pharmaceutical products, Pharmaceutical Research and Manufacturers of America (PhRMA). She advised the association on issues related to government enforcement of healthcare fraud and abuse laws, corporate compliance programs, patient adherence and access programs, and drug distribution channels.\nIn private practice, Lauren advised companies on compliance with healthcare regulations, including the Federal Food, Drug, and Cosmetic Act; the False Claims Act; the anti-kickback statute; and exclusion and debarment laws. She also guided healthcare companies in government investigations (criminal and civil) and conducted internal investigations to analyze legal risk and compliance issues.\nLauren earned her J.D. from the University of Virginia, where she served as an Articles Editor for the Virginia Law Review. Partner FDA Award of Merit 2023 University of Virginia  University of Virginia University of Virginia School of Law District of Columbia Food \u0026amp; Drug Law Institute","searchable_name":"Lauren K. Roth","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":435809,"version":1,"owner_type":"Person","owner_id":6591,"payload":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","slug":"sean-royall","email":"sroyall@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":129,"guid":"129.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":2,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":3,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":4,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":7,"source":"capabilities"},{"id":1147,"guid":"1147.smart_tags","index":8,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":9,"source":"smartTags"},{"id":1141,"guid":"1141.smart_tags","index":10,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":11,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":12,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":13,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":14,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":15,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":16,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":17,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":18,"source":"smartTags"},{"id":1,"guid":"1.capabilities","index":19,"source":"capabilities"},{"id":1248,"guid":"1248.smart_tags","index":20,"source":"smartTags"}],"is_active":true,"last_name":"Royall","nick_name":"M. Sean","clerkships":[{"name":"Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit","years_held":"1990 - 1991"}],"first_name":"M. Sean","title_rank":9999,"updated_by":202,"law_schools":[{"id":2174,"meta":{"degree":"J.D.","honors":"cum laude, Law Review","is_law_school":"1","graduation_date":"1990-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"","name_suffix":"","recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}],"linked_in_url":"https://www.linkedin.com/in/sean-royall-16964b232/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11010}]},"capability_group_id":3},"created_at":"2025-08-27T18:44:30.000Z","updated_at":"2025-08-27T18:44:30.000Z","searchable_text":"Royall{{ FIELD }}{:title=\u0026gt;\"Ranked Band 1 for Antitrust, Texas\", :detail=\u0026gt;\"Chambers USA, 2007–2023\"}{{ FIELD }}{:title=\u0026gt;\"Top ranked for Antitrust USA\", :detail=\u0026gt;\"Chambers Global, 2020–2023\"}{{ FIELD }}{:title=\u0026gt;\"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work\", :detail=\u0026gt;\"Benchmark Litigation, 2023\"}{{ FIELD }}{:title=\u0026gt;\"Named “Highly Recommended (Texas)”\", :detail=\u0026gt;\"Global Competition Review, 2022\"}{{ FIELD }}{:title=\u0026gt;\"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)\", :detail=\u0026gt;\"LMG Life Sciences\"}{{ FIELD }}{:title=\u0026gt;\"Named as one of “500 Leading Litigators in America”\", :detail=\u0026gt;\"Lawdragon, 2022 and 2024\"}{{ FIELD }}{:title=\u0026gt;\"Listed\", :detail=\u0026gt;\"Who’s Who Legal in Competition, 2021\"}{{ FIELD }}{:title=\u0026gt;\"Named “Litigation: Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2019\"}{{ FIELD }}{:title=\u0026gt;\"Named “Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2015 and 2018\"}{{ FIELD }}{:title=\u0026gt;\"Listed in “All-Star List”\", :detail=\u0026gt;\"BTI Services, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Named “Mergers and Acquisitions and Antitrust Trailblazer”\", :detail=\u0026gt;\"National Law Journal, 2015\"}{{ FIELD }}{:title=\u0026gt;\"Named “National Antitrust MVP”\", :detail=\u0026gt;\"Law360, 2015\"}{{ FIELD }}Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement.{{ FIELD }}In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.{{ FIELD }}U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.{{ FIELD }}In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.{{ FIELD }}U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss.{{ FIELD }}FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.{{ FIELD }}U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.{{ FIELD }}SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.{{ FIELD }}Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.{{ FIELD }}Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.{{ FIELD }}Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.{{ FIELD }}Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery.{{ FIELD }}Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.{{ FIELD }}U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.{{ FIELD }}FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.{{ FIELD }}Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.{{ FIELD }}Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.{{ FIELD }}In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.{{ FIELD }}Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.{{ FIELD }}Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.{{ FIELD }}Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.{{ FIELD }}Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.{{ FIELD }}Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.{{ FIELD }}U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*{{ FIELD }}Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.{{ FIELD }}Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict.{{ FIELD }}Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.{{ FIELD }}Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit.{{ FIELD }}AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner.{{ FIELD }}AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV.{{ FIELD }}Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.{{ FIELD }}Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.{{ FIELD }}Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation.{{ FIELD }}Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.{{ FIELD }}Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.{{ FIELD }}ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.{{ FIELD }}Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp.{{ FIELD }}Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin.{{ FIELD }}United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI.{{ FIELD }}Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com.{{ FIELD }}Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.{{ FIELD }}DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.{{ FIELD }}Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.{{ FIELD }}Sean Royall serves as the firm’s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country’s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.\nSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC’s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\nWhile in government, Sean was the lead trial lawyer in the FTC’s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company’s victory over the Department of Justice’s antitrust challenge to AT\u0026amp;T’s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\nSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC’s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator. \nFor well more than a decade, Sean has been given a Band 1 ranking by Chambers USA (2007-2025), which has described him as “top of the field,” “a star in the antitrust world both in counseling and litigation,” and an “extremely talented lawyer and exceptional litigator.”\nSean’s other recognitions include being ranked in Chambers Global for Antitrust – USA (2020-2023); endorsed as “Highly Recommended (Texas)” by Global Competition Review (2025); named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by Benchmark Litigation (2023). He is named by Lexology as a \"Competition Thought Leader\" (2025);  The Best Lawyers in America as “Antitrust Lawyer of the Year” (2015, 2018); and The Best Lawyers in America as “Litigation: Antitrust Lawyer of the Year” (2019). He has also been named to the “All-Star List” by BTI Services (2017) and deemed a “National Antitrust MVP” by Law360 (2015); a “Mergers and Acquisitions and Antitrust Trailblazer” by National Law Journal (2015); and a “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) by LMG Life Sciences. For the fourth year in a row, Sean was also named by Lawdragon as one of the \"500 Leading Litigators in America.\"\nPublications\nSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA’s Antitrust Law Journal, and as an editor of the ABA’s Antitrust magazine and of the Von Kalinowski treatise on Antitrust Laws and Trade Regulation.\n\nAuthor, “A Google Breakup Would Serve Progressive Aims and Punish Business,” Bloomberg Law, October 5, 2023.\nAuthor, “The FTC’s Punctuated Equilibrium,” ABA Antitrust Magazine, September 2023.\nAuthor, “The FTC’s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges” ABA Antitrust Magazine, September 9, 2022.\nAuthor, “Antitrust and Consumer Protection at Last Converge,” Corporate Counsel, April 27, 2022.\nQuoted in, “CFPB May Fill Enforcement Gap After FTC’s High Court Loss,” Law360, May 6, 2021.\nQuoted in, “By the Numbers: 5 Practices That Could Drive Big Law in 2021,” Bloomberg Law, December 23, 2020.\nQuoted in, “‘Hipster Antitrust’ Comes for Joe Biden,” New York Times, November 13, 2020.\n“A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,” ABA Antitrust Magazine, August 9, 2020.\n“The Intersection of Antitrust and the False Claims Act,” Headnotes, Dallas Bar Association, June 2020.\n“Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,” WLF Legal Pulse, March 9, 2020.\n“Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,” ABA Antitrust Magazine, December 12, 2019.\n“Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, September 3, 2019.\n“Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,” WLF Legal Pulse, August 7, 2019.\n“Ninth Circuit Judges Call for En Banc Review of FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, January 15, 2019.\nCo-author, “Lessons from FTC’s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,” WLF Legal Pulse, October 23, 2018.\nCo-author, “Are Disgorgement’s Days Numbered? Kokesh v. SEC May Foreshadow Curtailment of the FTC’s Authority to Obtain Monetary Relief,” ABA Antitrust Magazine, Spring 2018.\n“Will Kokesh v. FTC Put a Kink in the Federal Trade Commission’s Disgorgement Hose?” WLF Legal Pulse, July 10, 2017.\n“Antitrust Scrutiny of Pharmaceutical Product Hopping,” ABA Antitrust Magazine, Fall 2013.\n“When Mergers Become a Private Matter: An Updated Antitrust Primer,” ABA Antitrust Magazine, Spring 2012.\n“Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,” ABA Antitrust Magazine, Fall 2010.\n“The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,” ABA Antitrust Magazine, Spring 2010.\n“Change?: Merger Enforcement in the New Administration,” The Advocate, Summer 2009.\n“Deterring ‘Patent Ambush’ in Standard Setting: Lessons from Rambus and Qualcomm,” ABA Antitrust Magazine, Summer 2009.\n“The FTC’s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,” ABA Antitrust Magazine, Summer 2008.\n“Avoiding the Scarlet ‘S’: The Modern Challenges of Document Preservation and Destruction,” The American Lawyer, June 2005.\n“The Art of Destruction,” The American Lawyer, September 2004.\n“Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,” Antitrust, 2004.\n“Administrative Litigation at the FTC: Past, Present, and Future,” Antitrust Law Journal, 2003.\n“Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,” Antitrust, 2001.\n“Coping with the Antitrust Risks of Technological Integration,” Antitrust Law Journal, 2000.\n“Disaggregation of Antitrust Damages,” Antitrust Law Journal, 1997.\n“Post-Chicago Economics,” Antitrust Law Journal, 1995.\n Partner Ranked Band 1 for Antitrust, Texas Chambers USA, 2007–2023 Top ranked for Antitrust USA Chambers Global, 2020–2023 Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work Benchmark Litigation, 2023 Named “Highly Recommended (Texas)” Global Competition Review, 2022 Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) LMG Life Sciences Named as one of “500 Leading Litigators in America” Lawdragon, 2022 and 2024 Listed Who’s Who Legal in Competition, 2021 Named “Litigation: Antitrust Lawyer of the Year” The Best Lawyers in America, 2019 Named “Antitrust Lawyer of the Year” The Best Lawyers in America, 2015 and 2018 Listed in “All-Star List” BTI Services, 2017 Named “Mergers and Acquisitions and Antitrust Trailblazer” National Law Journal, 2015 Named “National Antitrust MVP” Law360, 2015 Texas A\u0026amp;M University Texas A\u0026amp;M School of Law University of Chicago University of Chicago Law School U.S. Court of Appeals for the Federal Circuit U.S. Court of Appeals for the Third Circuit U.S. Court of Appeals for the Fifth Circuit U.S. District Court for the Northern District of Texas U.S. District Court for the Southern District of Texas District of Columbia Texas Senior Courts of England and Wales Current Practicing Certificate in Victoria (Australia) Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement. In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments. U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry. In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement. U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss. FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably. U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit. SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance. Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal. Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss. Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court. Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery. Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims. U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit. FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability. Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims. Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery. In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims. Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information. Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial. Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement. Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims. Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines. U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.* Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue. Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict. Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement. Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit. AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner. AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV. Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation. Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations. Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation. Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP. Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments. ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues. Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp. Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin. United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI. Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com. Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical. DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters. Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.","searchable_name":"M. Sean Royall","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":436477,"version":1,"owner_type":"Person","owner_id":5088,"payload":{"bio":"\u003cp\u003eNeal J. Reynolds is a senior counsel in the firm\u0026rsquo;s international trade and litigation practice group.\u0026nbsp; He has more than twenty-five years of experience in international trade policy and litigation, with extensive experience in U.S. antidumping, countervailing duty, and safeguards investigations and reviews. \u0026nbsp;At King and Spalding, Neal focuses on international trade litigation and international trade policy.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eBefore joining King and Spalding, Neal was an international trade lawyer at the U.S. International Trade Commission for 22 years.\u0026nbsp; At the Commission, Neal provided legal and policy advice to the Commission and its staff in antidumping and countervailing duty proceedings and safeguard investigations.\u0026nbsp; He also represented the agency in litigation matters and provided advice to the Commission on a variety of trade policy issues.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFrom 2005 to 2014, Neal supervised the Commission\u0026rsquo;s legal staff in appeals of the agency\u0026rsquo;s trade remedy determinations, representing the Commission in a large number of appeals at the U.S. Court of International Trade, the U.S. Court of Appeals for the Federal Circuit, other Federal district and circuit courts, the World Trade Organization, and North American Free Trade Agreement dispute panels.\u0026nbsp; From 2014 to 2016, Neal was the Commission\u0026rsquo;s Chief of Staff, managing all of the agency\u0026rsquo;s operational and administrative activities.\u003c/p\u003e\n\u003cp\u003eBefore joining the Commission, Neal was a trade lawyer in the private sector for six years, representing clients before the Commission, the Department of Commerce, the Court of International Trade, and the Court of Appeals for the Federal Circuit.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDuring his career, Neal has worked on matters involving a variety of products, including carbon steel flat products, pipe and tube products, stainless steel products, wire and wire rod products, advanced electronic and consumer goods, tires, chemicals, bearings products, solar panels, large civil aircraft, cement, lumber, paper products, bedroom furniture, brass sheet and strip, flooring, uranium, wind towers, and agricultural products (such as beef, sugar and shrimp).\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBecause of his long experience in the area, Neal possesses a strong understanding of the trade remedy process and the Commission\u0026rsquo;s decision-making process. Neal has a strong track record of developing successful litigation strategies in litigation involving the Commission\u0026rsquo;s trade determinations.\u003c/p\u003e\n\u003cp\u003eNeal was a member of the Board of Directors of the Federal Circuit Bar Association from 2013 to 2017.\u0026nbsp; He was also Co-Chairman and Vice Chairman of the Federal Circuit Bar Association\u0026rsquo;s International Trade Committee from August 2010 to May 2013.\u0026nbsp;\u0026nbsp; Neal has spoken frequently on international trade issues and published a number of articles on trade remedy issues.\u003c/p\u003e","slug":"neal-reynolds","email":"nreynolds@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":579,"guid":"579.smart_tags","index":2,"source":"smartTags"},{"id":124,"guid":"124.capabilities","index":3,"source":"capabilities"}],"is_active":true,"last_name":"Reynolds","nick_name":"Neal","clerkships":[],"first_name":"Neal","title_rank":9999,"updated_by":34,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1986-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"J.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":77,"translated_fields":{"en":{"bio":"\u003cp\u003eNeal J. Reynolds is a senior counsel in the firm\u0026rsquo;s international trade and litigation practice group.\u0026nbsp; He has more than twenty-five years of experience in international trade policy and litigation, with extensive experience in U.S. antidumping, countervailing duty, and safeguards investigations and reviews. \u0026nbsp;At King and Spalding, Neal focuses on international trade litigation and international trade policy.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eBefore joining King and Spalding, Neal was an international trade lawyer at the U.S. International Trade Commission for 22 years.\u0026nbsp; At the Commission, Neal provided legal and policy advice to the Commission and its staff in antidumping and countervailing duty proceedings and safeguard investigations.\u0026nbsp; He also represented the agency in litigation matters and provided advice to the Commission on a variety of trade policy issues.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFrom 2005 to 2014, Neal supervised the Commission\u0026rsquo;s legal staff in appeals of the agency\u0026rsquo;s trade remedy determinations, representing the Commission in a large number of appeals at the U.S. Court of International Trade, the U.S. Court of Appeals for the Federal Circuit, other Federal district and circuit courts, the World Trade Organization, and North American Free Trade Agreement dispute panels.\u0026nbsp; From 2014 to 2016, Neal was the Commission\u0026rsquo;s Chief of Staff, managing all of the agency\u0026rsquo;s operational and administrative activities.\u003c/p\u003e\n\u003cp\u003eBefore joining the Commission, Neal was a trade lawyer in the private sector for six years, representing clients before the Commission, the Department of Commerce, the Court of International Trade, and the Court of Appeals for the Federal Circuit.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDuring his career, Neal has worked on matters involving a variety of products, including carbon steel flat products, pipe and tube products, stainless steel products, wire and wire rod products, advanced electronic and consumer goods, tires, chemicals, bearings products, solar panels, large civil aircraft, cement, lumber, paper products, bedroom furniture, brass sheet and strip, flooring, uranium, wind towers, and agricultural products (such as beef, sugar and shrimp).\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBecause of his long experience in the area, Neal possesses a strong understanding of the trade remedy process and the Commission\u0026rsquo;s decision-making process. Neal has a strong track record of developing successful litigation strategies in litigation involving the Commission\u0026rsquo;s trade determinations.\u003c/p\u003e\n\u003cp\u003eNeal was a member of the Board of Directors of the Federal Circuit Bar Association from 2013 to 2017.\u0026nbsp; He was also Co-Chairman and Vice Chairman of the Federal Circuit Bar Association\u0026rsquo;s International Trade Committee from August 2010 to May 2013.\u0026nbsp;\u0026nbsp; Neal has spoken frequently on international trade issues and published a number of articles on trade remedy issues.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5623}]},"capability_group_id":2},"created_at":"2025-09-02T04:55:31.000Z","updated_at":"2025-09-02T04:55:31.000Z","searchable_text":"Reynolds{{ FIELD }}Neal J. Reynolds is a senior counsel in the firm’s international trade and litigation practice group.  He has more than twenty-five years of experience in international trade policy and litigation, with extensive experience in U.S. antidumping, countervailing duty, and safeguards investigations and reviews.  At King and Spalding, Neal focuses on international trade litigation and international trade policy.\nBefore joining King and Spalding, Neal was an international trade lawyer at the U.S. International Trade Commission for 22 years.  At the Commission, Neal provided legal and policy advice to the Commission and its staff in antidumping and countervailing duty proceedings and safeguard investigations.  He also represented the agency in litigation matters and provided advice to the Commission on a variety of trade policy issues. \nFrom 2005 to 2014, Neal supervised the Commission’s legal staff in appeals of the agency’s trade remedy determinations, representing the Commission in a large number of appeals at the U.S. Court of International Trade, the U.S. Court of Appeals for the Federal Circuit, other Federal district and circuit courts, the World Trade Organization, and North American Free Trade Agreement dispute panels.  From 2014 to 2016, Neal was the Commission’s Chief of Staff, managing all of the agency’s operational and administrative activities.\nBefore joining the Commission, Neal was a trade lawyer in the private sector for six years, representing clients before the Commission, the Department of Commerce, the Court of International Trade, and the Court of Appeals for the Federal Circuit. \nDuring his career, Neal has worked on matters involving a variety of products, including carbon steel flat products, pipe and tube products, stainless steel products, wire and wire rod products, advanced electronic and consumer goods, tires, chemicals, bearings products, solar panels, large civil aircraft, cement, lumber, paper products, bedroom furniture, brass sheet and strip, flooring, uranium, wind towers, and agricultural products (such as beef, sugar and shrimp).       \nBecause of his long experience in the area, Neal possesses a strong understanding of the trade remedy process and the Commission’s decision-making process. Neal has a strong track record of developing successful litigation strategies in litigation involving the Commission’s trade determinations.\nNeal was a member of the Board of Directors of the Federal Circuit Bar Association from 2013 to 2017.  He was also Co-Chairman and Vice Chairman of the Federal Circuit Bar Association’s International Trade Committee from August 2010 to May 2013.   Neal has spoken frequently on international trade issues and published a number of articles on trade remedy issues. Senior Counsel Harvard University Harvard Law School Georgetown University Georgetown University Law Center U.S. Court of International Trade District of Columbia Massachusetts Federal Circuit Bar Association District of Columbia Bar Association Massachusetts Bar Association","searchable_name":"Neal J. Reynolds","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":427667,"version":1,"owner_type":"Person","owner_id":1348,"payload":{"bio":"\u003cp\u003eGillian Russell has over 15 years of experience counseling pharmaceutical, medical device, and cosmetic clients on a wide range of regulatory, compliance, and enforcement issues, with a focus on regulatory strategies and initiatives for the labeling, promotion and advertising of FDA-regulated products. Gillian frequently serves as legal counsel on Medical/Legal/Regulatory (MLR) committees and medical/scientific review committees and is known for providing practical and actionable advice and solutions. Gillian routinely advises on the full spectrum of promotional and non-promotional communications, including new product launches, direct-to-consumer promotion, social media, influencer marketing, and payer communications.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGillian graduated from the University of Virginia School of Law, where she served as Executive Editor for the\u0026nbsp;\u003cem\u003eVirginia Environmental Law Journal\u003c/em\u003e\u0026nbsp;and as a Hardy Cross Dillard fellow for legal research and writing. Gillian earned her B.A. magna cum laude from Princeton University, where she was a four-year member of the swimming team.\u0026nbsp;\u003c/p\u003e","slug":"gillian-russell","email":"grussell@kslaw.com","phone":null,"matters":["\u003cp\u003e\u0026ldquo;Industry Update \u0026ndash; New FDA Guidance on Social Media,\u0026rdquo; FX Conferences (September 2014).\u003c/p\u003e","\u003cp\u003e\u0026ldquo;The New Drug Approval Process: New Drug Research and Development,\u0026rdquo; FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"}],"is_active":true,"last_name":"Russell","nick_name":"Gillian","clerkships":[],"first_name":"Gillian","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"M.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eGillian Russell has over 15 years of experience counseling pharmaceutical, medical device, and cosmetic clients on a wide range of regulatory, compliance, and enforcement issues, with a focus on regulatory strategies and initiatives for the labeling, promotion and advertising of FDA-regulated products. Gillian frequently serves as legal counsel on Medical/Legal/Regulatory (MLR) committees and medical/scientific review committees and is known for providing practical and actionable advice and solutions. Gillian routinely advises on the full spectrum of promotional and non-promotional communications, including new product launches, direct-to-consumer promotion, social media, influencer marketing, and payer communications.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGillian graduated from the University of Virginia School of Law, where she served as Executive Editor for the\u0026nbsp;\u003cem\u003eVirginia Environmental Law Journal\u003c/em\u003e\u0026nbsp;and as a Hardy Cross Dillard fellow for legal research and writing. Gillian earned her B.A. magna cum laude from Princeton University, where she was a four-year member of the swimming team.\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003e\u0026ldquo;Industry Update \u0026ndash; New FDA Guidance on Social Media,\u0026rdquo; FX Conferences (September 2014).\u003c/p\u003e","\u003cp\u003e\u0026ldquo;The New Drug Approval Process: New Drug Research and Development,\u0026rdquo; FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6074}]},"capability_group_id":2},"created_at":"2025-05-26T05:03:27.000Z","updated_at":"2025-05-26T05:03:27.000Z","searchable_text":"Russell{{ FIELD }}“Industry Update – New FDA Guidance on Social Media,” FX Conferences (September 2014).{{ FIELD }}“The New Drug Approval Process: New Drug Research and Development,” FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).{{ FIELD }}Gillian Russell has over 15 years of experience counseling pharmaceutical, medical device, and cosmetic clients on a wide range of regulatory, compliance, and enforcement issues, with a focus on regulatory strategies and initiatives for the labeling, promotion and advertising of FDA-regulated products. Gillian frequently serves as legal counsel on Medical/Legal/Regulatory (MLR) committees and medical/scientific review committees and is known for providing practical and actionable advice and solutions. Gillian routinely advises on the full spectrum of promotional and non-promotional communications, including new product launches, direct-to-consumer promotion, social media, influencer marketing, and payer communications.\nGillian graduated from the University of Virginia School of Law, where she served as Executive Editor for the Virginia Environmental Law Journal and as a Hardy Cross Dillard fellow for legal research and writing. Gillian earned her B.A. magna cum laude from Princeton University, where she was a four-year member of the swimming team.  Counsel Princeton University  University of Virginia University of Virginia School of Law District of Columbia New Jersey Pennsylvania “Industry Update – New FDA Guidance on Social Media,” FX Conferences (September 2014). “The New Drug Approval Process: New Drug Research and Development,” FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).","searchable_name":"Gillian M. Russell","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":426489,"version":1,"owner_type":"Person","owner_id":5203,"payload":{"bio":"\u003cp\u003eJessica Rennert is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica earned her law degree from the University of Virginia School of Law. During law school, she was a Legal Writing Fellow and served on the managing board of the\u0026nbsp;\u003cem\u003eVirginia Law \u0026amp; Business Review\u003c/em\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJessica earned her B.A. in Foreign Affairs, with distinction, from the University of Virginia.\u0026nbsp;\u003c/p\u003e","slug":"jessica-rennert","email":"jrennert@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":1241,"guid":"1241.smart_tags","index":0,"source":"smartTags"}],"is_active":true,"last_name":"Rennert","nick_name":"Jessica","clerkships":[],"first_name":"Jessica","title_rank":9999,"updated_by":101,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2020-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eJessica Rennert is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica earned her law degree from the University of Virginia School of Law. During law school, she was a Legal Writing Fellow and served on the managing board of the\u0026nbsp;\u003cem\u003eVirginia Law \u0026amp; Business Review\u003c/em\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJessica earned her B.A. in Foreign Affairs, with distinction, from the University of Virginia.\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10025}]},"capability_group_id":null},"created_at":"2025-05-26T04:53:46.000Z","updated_at":"2025-05-26T04:53:46.000Z","searchable_text":"Rennert{{ FIELD }}Jessica Rennert is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her practice focuses on government investigations, white-collar criminal defense, and related civil litigation.\nJessica earned her law degree from the University of Virginia School of Law. During law school, she was a Legal Writing Fellow and served on the managing board of the Virginia Law \u0026amp; Business Review. \nJessica earned her B.A. in Foreign Affairs, with distinction, from the University of Virginia.  Associate University of Virginia University of Virginia School of Law University of Virginia University of Virginia School of Law District of Columbia","searchable_name":"Jessica Rennert","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":447419,"version":1,"owner_type":"Person","owner_id":7320,"payload":{"bio":"\u003cp\u003eAlicia Rose is an associate in King \u0026amp; Spalding\u0026rsquo;s International Trade team. Alicia advises on a wide range of regulatory and compliance matters, including U.S. economic sanctions, export controls, CFIUS, and anti-money laundering laws and regulations. Alicia also has experience working on government and internal investigations and enforcement matters in the financial services, crypto, energy, shipping, and nonprofit sectors.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAlicia has\u0026nbsp;advised\u0026nbsp;clients on regulatory\u0026nbsp;compliance and\u0026nbsp;assisting\u0026nbsp;with license applications, voluntary self-disclosures, subpoena\u0026nbsp;responses, and other submissions to\u0026nbsp;government agencies.\u0026nbsp;Alicia\u0026nbsp;has\u0026nbsp;also\u0026nbsp;represented companies and individuals under investigation by the Department of Justice\u0026nbsp;(DOJ), Office of Foreign Assets Control\u0026nbsp;(OFAC), Federal Reserve Board,\u0026nbsp;and\u0026nbsp;New York Department of Financial Services.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alicia worked\u0026nbsp;in the litigation and investigations practice of\u0026nbsp;a global law firm\u0026nbsp;where\u0026nbsp;her practice focused primarily on\u0026nbsp;complex criminal and regulatory enforcement matters and internal investigations involving allegations of economic\u0026nbsp;sanctions, money laundering, AML/BSA violations,\u0026nbsp;or\u0026nbsp;corruption.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDuring law school, Alicia interned with the U.S. Court of International Trade.\u0026nbsp;Alicia was also Co-Editor-in-Chief of the UCLA Journal of International Law and Foreign Affairs.\u0026nbsp;\u003c/p\u003e","slug":"alicia-rose","email":"arose@kslaw.com","phone":null,"matters":["\u003cp\u003eCounseled DOJ\u0026rsquo;s independent monitor of a global cryptocurrency exchange, in connection with its USD 4.3 billion BSA / AML and sanctions resolution with DOJ.*\u003c/p\u003e","\u003cp\u003eRepresented a Danish financial institution in relation to investigations by DOJ, the SEC, and Danish criminal authorities arising from money laundering allegations involving its former Estonian branch, resulting in a USD 2 billion global settlement.*\u003c/p\u003e","\u003cp\u003eRepresented an Italian financial institution in connection with compliance obligations arising from its settlements with DOJ, the District Attorney of New York County, the Federal Reserve, OFAC and the New York State Department of Financial Services, following USD 1.3 billion global economic sanctions resolution.*\u003c/p\u003e","\u003cp\u003eRepresented various companies and individuals in cross-border investigations by OFAC, DOJ, FBI, and other agencies relating to potential violations of sanctions, money laundering, or anti-corruption laws.*\u003c/p\u003e","\u003cp\u003eCounseled various international financial institutions and companies on U.S. sanctions or export control risks related to transactions involving Russia, Cuba, Iran, China, Syria, Venezuela, and Libya.*\u003c/p\u003e","\u003cp\u003eCounseled various companies in connection with U.S. sanctions-related due diligence and compliance representations, warranties and covenants.*\u003c/p\u003e","\u003cp\u003e* Denotes experience prior to joining King \u0026amp; Spalding\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":5065}]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":2,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":3,"source":"capabilities"},{"id":128,"guid":"128.capabilities","index":4,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":5,"source":"capabilities"},{"id":803,"guid":"803.smart_tags","index":6,"source":"smartTags"},{"id":1330,"guid":"1330.smart_tags","index":7,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":8,"source":"smartTags"},{"id":1327,"guid":"1327.smart_tags","index":9,"source":"smartTags"}],"is_active":true,"last_name":"Rose","nick_name":"Alicia","clerkships":[{"name":"Intern, Hon. Timothy M. Reif, U.S. Court of International Trade","years_held":"2021 - 2021"}],"first_name":"Alicia","title_rank":9999,"updated_by":202,"law_schools":[{"id":3168,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2021-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/aliciarose215","seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eAlicia Rose is an associate in King \u0026amp; Spalding\u0026rsquo;s International Trade team. Alicia advises on a wide range of regulatory and compliance matters, including U.S. economic sanctions, export controls, CFIUS, and anti-money laundering laws and regulations. Alicia also has experience working on government and internal investigations and enforcement matters in the financial services, crypto, energy, shipping, and nonprofit sectors.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAlicia has\u0026nbsp;advised\u0026nbsp;clients on regulatory\u0026nbsp;compliance and\u0026nbsp;assisting\u0026nbsp;with license applications, voluntary self-disclosures, subpoena\u0026nbsp;responses, and other submissions to\u0026nbsp;government agencies.\u0026nbsp;Alicia\u0026nbsp;has\u0026nbsp;also\u0026nbsp;represented companies and individuals under investigation by the Department of Justice\u0026nbsp;(DOJ), Office of Foreign Assets Control\u0026nbsp;(OFAC), Federal Reserve Board,\u0026nbsp;and\u0026nbsp;New York Department of Financial Services.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alicia worked\u0026nbsp;in the litigation and investigations practice of\u0026nbsp;a global law firm\u0026nbsp;where\u0026nbsp;her practice focused primarily on\u0026nbsp;complex criminal and regulatory enforcement matters and internal investigations involving allegations of economic\u0026nbsp;sanctions, money laundering, AML/BSA violations,\u0026nbsp;or\u0026nbsp;corruption.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDuring law school, Alicia interned with the U.S. Court of International Trade.\u0026nbsp;Alicia was also Co-Editor-in-Chief of the UCLA Journal of International Law and Foreign Affairs.\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003eCounseled DOJ\u0026rsquo;s independent monitor of a global cryptocurrency exchange, in connection with its USD 4.3 billion BSA / AML and sanctions resolution with DOJ.*\u003c/p\u003e","\u003cp\u003eRepresented a Danish financial institution in relation to investigations by DOJ, the SEC, and Danish criminal authorities arising from money laundering allegations involving its former Estonian branch, resulting in a USD 2 billion global settlement.*\u003c/p\u003e","\u003cp\u003eRepresented an Italian financial institution in connection with compliance obligations arising from its settlements with DOJ, the District Attorney of New York County, the Federal Reserve, OFAC and the New York State Department of Financial Services, following USD 1.3 billion global economic sanctions resolution.*\u003c/p\u003e","\u003cp\u003eRepresented various companies and individuals in cross-border investigations by OFAC, DOJ, FBI, and other agencies relating to potential violations of sanctions, money laundering, or anti-corruption laws.*\u003c/p\u003e","\u003cp\u003eCounseled various international financial institutions and companies on U.S. sanctions or export control risks related to transactions involving Russia, Cuba, Iran, China, Syria, Venezuela, and Libya.*\u003c/p\u003e","\u003cp\u003eCounseled various companies in connection with U.S. sanctions-related due diligence and compliance representations, warranties and covenants.*\u003c/p\u003e","\u003cp\u003e* Denotes experience prior to joining King \u0026amp; Spalding\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":13456}]},"capability_group_id":2},"created_at":"2026-04-08T13:39:28.000Z","updated_at":"2026-04-08T13:39:28.000Z","searchable_text":"Rose{{ FIELD }}Counseled DOJ’s independent monitor of a global cryptocurrency exchange, in connection with its USD 4.3 billion BSA / AML and sanctions resolution with DOJ.*{{ FIELD }}Represented a Danish financial institution in relation to investigations by DOJ, the SEC, and Danish criminal authorities arising from money laundering allegations involving its former Estonian branch, resulting in a USD 2 billion global settlement.*{{ FIELD }}Represented an Italian financial institution in connection with compliance obligations arising from its settlements with DOJ, the District Attorney of New York County, the Federal Reserve, OFAC and the New York State Department of Financial Services, following USD 1.3 billion global economic sanctions resolution.*{{ FIELD }}Represented various companies and individuals in cross-border investigations by OFAC, DOJ, FBI, and other agencies relating to potential violations of sanctions, money laundering, or anti-corruption laws.*{{ FIELD }}Counseled various international financial institutions and companies on U.S. sanctions or export control risks related to transactions involving Russia, Cuba, Iran, China, Syria, Venezuela, and Libya.*{{ FIELD }}Counseled various companies in connection with U.S. sanctions-related due diligence and compliance representations, warranties and covenants.*{{ FIELD }}* Denotes experience prior to joining King \u0026amp; Spalding{{ FIELD }}Alicia Rose is an associate in King \u0026amp; Spalding’s International Trade team. Alicia advises on a wide range of regulatory and compliance matters, including U.S. economic sanctions, export controls, CFIUS, and anti-money laundering laws and regulations. Alicia also has experience working on government and internal investigations and enforcement matters in the financial services, crypto, energy, shipping, and nonprofit sectors. \nAlicia has advised clients on regulatory compliance and assisting with license applications, voluntary self-disclosures, subpoena responses, and other submissions to government agencies. Alicia has also represented companies and individuals under investigation by the Department of Justice (DOJ), Office of Foreign Assets Control (OFAC), Federal Reserve Board, and New York Department of Financial Services. \nPrior to joining King \u0026amp; Spalding, Alicia worked in the litigation and investigations practice of a global law firm where her practice focused primarily on complex criminal and regulatory enforcement matters and internal investigations involving allegations of economic sanctions, money laundering, AML/BSA violations, or corruption.  \nDuring law school, Alicia interned with the U.S. Court of International Trade. Alicia was also Co-Editor-in-Chief of the UCLA Journal of International Law and Foreign Affairs.  Alicia Rose lawyer Associate George Washington University  University of California, Los Angeles, School of Law  District of Columbia New York Associate Member, U.S.-Japan Council Intern, Hon. Timothy M. Reif, U.S. Court of International Trade Counseled DOJ’s independent monitor of a global cryptocurrency exchange, in connection with its USD 4.3 billion BSA / AML and sanctions resolution with DOJ.* Represented a Danish financial institution in relation to investigations by DOJ, the SEC, and Danish criminal authorities arising from money laundering allegations involving its former Estonian branch, resulting in a USD 2 billion global settlement.* Represented an Italian financial institution in connection with compliance obligations arising from its settlements with DOJ, the District Attorney of New York County, the Federal Reserve, OFAC and the New York State Department of Financial Services, following USD 1.3 billion global economic sanctions resolution.* Represented various companies and individuals in cross-border investigations by OFAC, DOJ, FBI, and other agencies relating to potential violations of sanctions, money laundering, or anti-corruption laws.* Counseled various international financial institutions and companies on U.S. sanctions or export control risks related to transactions involving Russia, Cuba, Iran, China, Syria, Venezuela, and Libya.* Counseled various companies in connection with U.S. sanctions-related due diligence and compliance representations, warranties and covenants.* * Denotes experience prior to joining King \u0026amp; Spalding","searchable_name":"Alicia Rose","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}